How RNA is produced

Abstract

The present invention provides a method for producing RNA, which comprises culturing in a medium a coryneform bacterium having an expression unit for a target RNA that has been modified to reduce ribonuclease III activity, allowing the target RNA to be expressed and accumulated within the bacterial cells, and then collecting the target RNA from the bacterial cells.

Description

[Technical field]

[0001] The present invention relates to a method for producing RNA (ribonucleic acid) by fermentation using microorganisms. [Background technology]

[0002] Known methods for producing RNA using microorganisms include a method in which RNA is accumulated intracellularly using Escherichia coli lacking ribonuclease III (RNase III) as a host (Non-Patent Document 1), a method in which RNA is accumulated intracellularly using Pseudomonas syringae as a host by utilizing the function of φ6 bacteriophage (Non-Patent Document 2), a method in which RNA fused with a partial sequence of tRNA is accumulated intracellularly using Escherichia coli as a host (Non-Patent Document 3), a production method in which siRNA is formed as a complex with a protein that binds to it using Escherichia coli as a host (Non-Patent Document 4), a method in which RNA is secreted and produced using bacteria of the genus Rhodovulum as a host (Patent Document 1), and a method in which RNA is accumulated in yeast mitochondria using yeast as a host (Patent Document 2). [Prior art documents] [Patent documents]

[0003] [Patent Document 1] WO2009 / 063969 [Patent Document 2] WO2010 / 084371 [Non-patent literature]

[0004] [Non-Patent Document 1] Tenllado F, et. al., Crude extracts of bacterially expressed dsRNA can be used to protect plants against virus infections. BMC Biotechnol. 2003 Mar 20;3:3. [Non-Patent Document 2] Aalto AP, et. al., Large-scale production of dsRNA and siRNA pools for RNA interference utilizing bacteriophage phi6 RNA-dependent RNA polymerase. RNA. 2007 Mar;13(3):422-9. [Non-Patent Document 3] Ponchon L, et. al., A generic protocol for the expression and purification of recombinant RNA in Escherichia coli using a tRNA scaffold. Nat Protoc. 2009;4(6):947-59. [Non-Patent Document 4] Huang L, et. al., Efficient and specific gene knockdown by small interfering RNAs produced in bacteria. Nat Biotechnol. 2013 Apr;31(4):350-6. Summary of the Invention [Problem to be solved by the invention]

[0005] An objective of the present invention is to provide an efficient method for producing RNA. [Means for solving the problem]

[0006] The present inventors discovered that RNA can be efficiently produced by expressing RNA in a coryneform bacterium lacking ribonuclease III (RNase III), and thus completed the present invention.

[0007] That is, the present invention can be exemplified as follows. [1] A method for producing a target RNA, comprising the steps of: Cultivating a coryneform bacterium having an expression unit for a target RNA in a medium, expressing the target RNA, and accumulating the target RNA in the cells of the bacterium; collecting target RNA from the bacterial cells; Including, The method, wherein the bacterium has been modified to reduce ribonuclease III activity compared to a non-modified strain. [2] The method, wherein the ribonuclease III is a protein described in the following (a), (b), or (c): (a) a protein comprising the amino acid sequence set forth in SEQ ID NO:52; (b) a protein comprising an amino acid sequence including a substitution, deletion, insertion, and / or addition of 1 to 10 amino acid residues in the amino acid sequence shown in SEQ ID NO: 52, and having RNase III activity; (c) a protein comprising an amino acid sequence having 90% or more identity to the amino acid sequence shown in SEQ ID NO:52 and having ribonuclease III activity. [3] The method as described above, wherein the activity of RNase III is reduced by reducing the expression of a gene encoding RNase III or by disrupting said gene. [4] The method as described above, wherein the activity of ribonuclease III is reduced by deleting a gene encoding ribonuclease III. [5] The method as described above, wherein the bacterium has the expression unit at a copy number of 5 copies / cell or more. [6] The method as described above, wherein the bacterium has the expression unit at a copy number of 70 copies / cell or more. [7] The method, wherein the bacterium comprises a vector comprising the expression unit. [8] The above method, wherein the expression unit comprises, in the 5' to 3' direction, a promoter sequence that functions in a coryneform bacterium and a nucleotide sequence that encodes a target RNA. [9] The method, wherein the promoter sequence is a phage-derived promoter.

[10] The method, wherein the promoter sequence is an F1 promoter or a T7 promoter.

[11] The method, wherein the promoter sequence is a promoter described in the following (a) or (b): (a) a promoter comprising the nucleotide sequence shown in SEQ ID NO: 13 or 78; (b) a promoter comprising a nucleotide sequence having 90% or more identity to the nucleotide sequence shown in SEQ ID NO: 13 or 78.

[12] The method as described above, wherein the bacterium is a Corynebacterium bacterium.

[13] The method, wherein the bacterium is Corynebacterium glutamicum. [Brief description of the drawings]

[0008] [Figure 1] FIG. 1 is a diagram showing the construction procedure of plasmid pPBS4SΔrnc. [Diagram 2] Agarose gel electrophoresis diagram (photo) to confirm rnc gene deletion. [Diagram 3] A diagram showing the construction procedure of plasmid pVC7-sacB. [Figure 4] A diagram showing the construction procedure of plasmid pVC7-Pf1-U1Ainsert. [Diagram 5]Diagram showing the construction procedure of the plasmids. (A) pVC7-Pf1-Hv-iap. (B) pVC7-Pf1-Hv-iap-Pf1rev. [Figure 6] Agarose gel electrophoresis diagram (photo) showing the effect of deleting the rnc gene on improving RNA production. [Figure 7] Agarose gel electrophoresis diagram (photo) showing the effect of increasing the copy number of an RNA expression plasmid on improving RNA production. [Figure 8] A diagram showing the construction procedure of plasmid pL4440-Pt7-U1Ainsert. [Figure 9] A diagram showing the construction procedure of plasmid pL4440-Pt7-Hv-iap-Pt7rev. [Figure 10] Agarose gel electrophoresis diagram (photo) showing the comparison of RNA production by the F1 promoter expression system in C. glutamicum and the T7 promoter inducible expression system in E. coli. [Figure 11] A diagram showing the construction procedure of plasmid pPK4 XB-T7 ter. [Figure 12] A diagram showing the construction procedure of plasmid pPK-T7lac. [Figure 13] A diagram showing the construction procedure of plasmid pPK-T7lac-vd-antiOlac. [Figure 14] A diagram showing the construction procedure of plasmid pVC54. [Figure 15] A diagram showing the construction procedure of plasmid pBS5t-ptrB*. [Figure 16] A diagram showing the construction procedure of plasmid pBS5t-ptrB*-2Ter. [Figure 17] A diagram showing the construction procedure of plasmid pBS5t-ptrB*-T7pol. [Figure 18] A diagram showing the construction procedure of plasmid pVC54-T7pol. [Figure 19]Agarose gel electrophoresis showing RNA production by the T7 promoter-inducible expression system in C. glutamicum (photo). Lanes 1-2 and 6-7: Clone A, Lanes 3-4 and 8-9: Clone B, Lane 5: Century-Plus RNA Marker (Ambion AM7145). [Figure 20] A diagram showing the construction procedure of plasmid pPK4-T7pol. [Figure 21] A diagram showing the construction procedure of plasmid pVC7-Pt7-Hv-iap-Pt7rev. [Figure 22] Agarose gel electrophoresis diagram showing RNA production by the T7 promoter-inducible expression system in C. glutamicum (photo). [Figure 23] Agarose gel electrophoresis diagram (photo) showing RNA production by the high-copy-number plasmid pPK4H1. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0009] The present invention will be described in detail below.

[0010] The method of the present invention is a method for producing a target RNA, comprising culturing a coryneform bacterium having an expression unit of a target RNA in a medium and harvesting the transcribed target RNA, wherein the bacterium has been modified to reduce RNase III activity. The coryneform bacterium used in the method is also referred to as the "bacterium of the present invention."

[0011] <1> The bacteria of the present invention The bacterium of the present invention is a coryneform bacterium having an expression unit for a target RNA which has been modified so as to reduce ribonuclease III activity.

[0012] The bacterium of the present invention can be obtained by introducing an expression unit of an RNA of interest and reducing the activity of ribonuclease III into a coryneform bacterium. In the present invention, the modifications for constructing the bacterium of the present invention can be performed in any order. That is, the bacterium of the present invention can be obtained, for example, by introducing an expression unit of an RNA of interest into a coryneform bacterium, and then modifying the coryneform bacterium so that the activity of ribonuclease III is reduced. The bacterium of the present invention can also be obtained, for example, by modifying a coryneform bacterium so that the activity of ribonuclease III is reduced, and then introducing an expression unit of an RNA of interest into the coryneform bacterium. The bacterium of the present invention or the bacterium from which it is constructed is also referred to as a "host".

[0013] The bacterium of the present invention has the ability to produce a target RNA (the ability to produce a target RNA). Specifically, the bacterium of the present invention has the ability to produce the target RNA based on having at least an expression unit for the target RNA. The bacterium of the present invention may have acquired the ability to produce the target RNA, for example, by introducing an expression unit for the target RNA, or by a combination of introducing an expression unit for the target RNA and reducing RNase III activity. That is, the strain used in constructing the bacterium of the present invention before being modified to reduce RNase III activity may or may not be able to produce the target RNA, assuming that it has an expression unit for the target RNA.

[0014] The bacterium of the present invention may have any properties as long as it has the ability to produce the target RNA. The bacterium of the present invention may or may not have a vector such as a plasmid other than the vector containing the expression unit of the target RNA. That is, for example, when the bacterium of the present invention inherently has a plasmid, the plasmid may be cured (removed).

[0015] <1-1> Corynebacterium capable of producing the target RNA In the present invention, the term "bacteria capable of producing a target RNA" refers to bacteria capable of expressing a target RNA when cultured in a medium and accumulating the target RNA in the cells to an extent that the target RNA can be collected. The bacterium capable of producing a target RNA may be a bacterium capable of accumulating a greater amount of the target RNA in the cells than a non-modified strain. The term "non-modified strain" refers to a control strain that has not been modified to reduce the activity of ribonuclease III. In other words, examples of non-modified strains include wild-type strains and parent strains. The bacterium capable of producing a target RNA may be a bacterium capable of accumulating a target RNA in the cells in an amount of, for example, 1 mg / L or more of culture medium, 2 mg / L or more of culture medium, 5 mg / L or more of culture medium, 10 mg / L or more of culture medium, 20 mg / L or more of culture medium, 50 mg / L or more of culture medium, or 100 mg / L or more of culture medium.

[0016] In the present invention, coryneform bacteria are used as hosts. Examples of coryneform bacteria include bacteria belonging to the genera Corynebacterium, Brevibacterium, Mycobacterium, and Microbacterium.

[0017] Specific examples of coryneform bacteria include the following species: Corynebacterium acetoacidophilum Corynebacterium acetoglutamicum Corynebacterium alkanolyticum Corynebacterium callunae Corynebacterium crenatum Corynebacterium glutamicum Corynebacterium lilium Corynebacterium melassecola Corynebacterium thermoaminogenes (Corynebacterium efficiens) Corynebacterium herculis Brevibacterium divaricatum (Corynebacterium glutamicum) Brevibacterium flavum (Corynebacterium glutamicum) flavum (Corynebacterium glutamicum)) Brevibacterium immariophilum Brevibacterium lactofermentum (Corynebacterium glutamicum) Brevibacterium roseum Brevibacterium saccharolyticum Brevibacterium thiogenitalis Corynebacterium ammoniagenes (Corynebacterium stationis) Brevibacterium album Brevibacterium cerinum Microbacterium ammoniaphilum

[0018] Specific examples of coryneform bacteria include the following strains: Corynebacterium acetoacidophilum ATCC 13870 Corynebacterium acetoglutamicum ATCC 15806 Corynebacterium alkanolyticum ATCC 21511 Corynebacterium callunae ATCC 15991 Corynebacterium crenatum AS1.542 Corynebacterium glutamicum ATCC 13020, ATCC 13032, ATCC 13060, ATCC 13869, FERM BP-734 Corynebacterium lilium ATCC 15990 Corynebacterium melassecola ATCC 17965 Corynebacterium efficiens (Corynebacterium thermoaminogenes) AJ12340 (FERM BP-1539) Corynebacterium herculis ATCC 13868 Brevibacterium divaricatum (Corynebacterium glutamicum) ATCC 14020 Brevibacterium flavum (Corynebacterium glutamicum) ATCC 13826, ATCC 14067, AJ12418 (FERM BP-2205) Brevibacterium immariophilum ATCC 14068 Brevibacterium lactofermentum (Corynebacterium glutamicum) ATCC 13869 Brevibacterium roseum ATCC 13825 Brevibacterium saccharolyticum ATCC 14066 Brevibacterium thiogenitalis ATCC 19240 Corynebacterium ammoniagenes (Corynebacterium stationis) ATCC 6871, ATCC 6872 Brevibacterium album ATCC 15111 Brevibacterium cerinum ATCC 15112 Microbacterium ammoniaphilum ATCC 15354

[0019] The genus Corynebacterium includes bacteria that were previously classified as Brevibacterium but have now been integrated into the genus Corynebacterium (Int. J. Syst. Bacteriol., 41, 255(1991)). Corynebacterium stathionis also includes bacteria that were previously classified as Corynebacterium ammoniagenes but have been reclassified as Corynebacterium stathionis based on the analysis of 16S rRNA sequences (Int. J. Syst. Evol. Microbiol., 60, 874-879(2010)).

[0020] These strains can be obtained, for example, from the American Type Culture Collection (Address: 12301 Parklawn Drive, Rockville, Maryland 20852 PO Box 1549, Manassas, VA 20108, United States of America). That is, a registration number corresponding to each strain is assigned, and the strains can be obtained by using the registration number (see http: / / www.atcc.org / ). The registration number corresponding to each strain is listed in the catalog of the American Type Culture Collection. In addition, these strains can be obtained, for example, from the depository institution where each strain was deposited.

[0021] <1-2> Introduction of target RNA expression unit The bacterium of the present invention has an expression unit for a target RNA. Lineagenform bacteria can be obtained by introducing an expression unit of a target RNA into a coryneform bacterium.

[0022] "Target RNA" refers to an RNA produced by the method of the present invention. In the present invention, one type of target RNA may be produced, or two or more types of target RNA may be produced.

[0023] The target RNA is not particularly limited as long as it is an RNA foreign to the host, that is, an RNA other than the host's RNA. The target RNA can be appropriately selected according to various conditions such as the intended use of the target RNA. The target RNA may be, for example, a naturally occurring RNA, a modified RNA thereof, or an artificially designed RNA. The target RNA may be, for example, an RNA derived from a microorganism, a plant, an animal, or a virus. The target RNA may be, for example, a messenger RNA (mRNA), or a non-coding RNA such as rRNA (ribosomal RNA), tRNA (transfer RNA), miRNA (micro RNA), siRNA (small interfering RNA), ribozyme, or RNA aptamer. The mRNA may code for a protein having some function such as an enzyme, a receptor, a transporter, an antibody, a structure, or a regulatory factor, or may code for a protein that does not have a function itself. The term "protein" as used herein also includes so-called peptides such as oligopeptides and polypeptides. The target RNA may be, for example, an RNA having the base sequence of the RNA described above. The target RNA may also be, for example, an RNA having a partial sequence of the base sequence of the RNA described above. The target RNA may also be, for example, an RNA having the base sequence of the RNA described above or a complementary sequence of the partial sequence. The target RNA may also be, for example, an RNA having a variant sequence of the base sequence of the RNA described above, the partial sequence, or the complementary sequence. The variant sequence can be mutatis mutandis as described below for the variant of the RNase III gene. The target RNA may also have a combination of two or more base sequences selected from the base sequence of the RNA described above, the partial sequence, the complementary sequence, and the variant sequence.Specific examples of target RNA include a partial sequence of the mRNA of an apoptosis inhibitor from the 20-spotted ladybird (Henosepilachna vigintioctopunctata) and a partial sequence of the mRNA of subunits A and E that constitute the ATPase in the vacuole of the Colorado potato beetle (Leptinotarsa ​​decemlineata).

[0024] The target RNA may be, for example, single-stranded RNA (RNA consisting of one RNA strand) or double-stranded RNA (RNA consisting of two RNA strands). The double-stranded RNA may be a double-stranded RNA consisting of a single type of RNA molecule (homoduplex) or a double-stranded RNA consisting of two different types of RNA molecules (heteroduplex). Specific examples of double-stranded RNA include double-stranded RNA consisting of a certain RNA strand and its complementary strand. The target RNA may also be a double-stranded RNA consisting of, for example, one RNA strand and one DNA strand. The target RNA may include both a single-stranded region and a double-stranded region. That is, for example, the single-stranded RNA may partially form a double-stranded structure (for example, a stem-loop structure) within the molecule. For example, the double-stranded RNA may also partially include a single-stranded structure.

[0025] The length of the target RNA is not particularly limited. The length of the target RNA may be, for example, 10 or more residues, 20 or more residues, 50 or more residues, or 100 or more residues, or 10,000 or less residues, 5,000 or less residues, 2,000 or less residues, 1,000 or less residues, or 500 or less residues, or a combination thereof.

[0026] "Expression unit of a target RNA" refers to a gene construct that is configured to be able to express a target RNA. The expression unit of a target RNA contains, from the 5' to 3' direction, a promoter sequence that functions in coryneform bacteria and a base sequence that codes for the target RNA. The promoter sequence is also simply called a "promoter." The base sequence that codes for a target RNA is also called a "gene that codes for a target RNA." The target RNA gene may be linked downstream of a promoter so that the target RNA is expressed under the control of the promoter. The expression unit of the target RNA may have a control sequence (such as an operator or terminator) effective for expressing the target RNA in a coryneform bacterium at an appropriate position so that the control sequence can function. In the present invention, the terms "expression of the target RNA gene", "transcription of the target RNA gene", "expression of the target RNA", and "transcription of the target RNA" can be used synonymously. The expression unit of the target RNA can be designed appropriately depending on various conditions such as the type of the target RNA and the transcription mode.

[0027] The transcription mode of the target RNA is not particularly limited as long as the target RNA is obtained. For example, the target RNA gene may be transcribed unidirectionally (i.e., using only one strand of the double strand as a template) or bidirectionally (i.e., using each strand of the double strand as a template). Bidirectional transcription of the target RNA gene can be performed by transcribing the gene from promoters arranged in opposite directions across the gene (i.e., promoters arranged on the 5' side of the gene in each strand of the double strand). That is, the expression unit of the target RNA may include such two promoters. In this case, both promoters may or may not be the same. By transcribing the target RNA gene unidirectionally, a single-stranded RNA is typically obtained. By transcribing the target RNA gene bidirectionally, a double-stranded RNA is typically obtained. In addition, a double-stranded RNA can also be obtained by transcribing each strand of the double-stranded RNA from an individual expression unit.

[0028] The target RNA gene can be obtained, for example, by cloning. For cloning, for example, nucleic acids such as genomic DNA or cDNA containing the target RNA gene can be used. The target RNA gene can also be obtained, for example, by total synthesis based on its base sequence (Gene, 60(1), 115-127 (1987)). The obtained target RNA gene can be used as is or after appropriate modification. That is, by modifying the target RNA gene, its variant can be obtained. Gene modification can be performed by known techniques. For example, a target mutation can be introduced into a target site of DNA by site-specific mutagenesis. Examples of site-specific mutagenesis include a method using PCR (Higuchi, R., 61, in PCR technology, Erlich, HA Eds., Stockton press (1989); Carter, P., Meth. in Enzymol., 154, 382 (1987)) and a method using phage (Kramer,W. and Frits, HJ, Meth. in Enzymol., 154, 350 (1987); Kunkel, TA et al., Meth. in Enzymol., 154, 367 (1987)). Alternatively, a variant of the target RNA gene may be totally synthesized. In addition, the obtained target RNA gene may be appropriately modified, such as by introducing a promoter sequence, to obtain an expression unit of the target RNA. In addition, other components of the expression unit of the target RNA (e.g., promoter sequence) and the entire expression unit of the target RNA may also be obtained in the same manner as the target RNA gene.

[0029] The promoter for expressing the target RNA gene is not particularly limited as long as it functions in the host. A "promoter that functions in the host" refers to a promoter that has promoter activity, i.e., gene transcription activity, in the host. The promoter may be a host-derived promoter or a heterologous promoter. The promoter may be an intrinsic promoter of the target RNA gene or a promoter of another gene. Furthermore, the promoter may be inducible or constitutive with respect to gene expression.

[0030] Examples of promoters include promoters of genes involved in glycolysis, the pentose phosphate pathway, the TCA cycle, the amino acid biosynthesis system, and cell surface proteins. In addition, stronger promoters such as those described below may be used as promoters. Stronger promoters include, for example, the artificially engineered P54-6 promoter (Appl. Microbiol. Biotechnolo., 53, 674-679 (2000)), which can be induced by acetate, ethanol, pyruvic acid, etc. Examples of the promoter include pta, aceA, aceB, adh, and amyE promoters, which are strong promoters, and other strong promoters such as cspB, SOD, and tuf promoters (Journal of Biotechnology 104 (2003) 311-323, Appl Environ Microbiol. 2005 Dec;71(12):8587-96.), lac promoter, tac promoter, trc promoter, F1 promoter, T7 promoter, T5 promoter, T3 promoter, and SP6 promoter. Examples of the promoter include, in particular, phage-derived promoters such as F1 promoter, T7 promoter, T5 promoter, T3 promoter, and SP6 promoter. Examples of the promoter include, in particular, F1 promoter and T7 promoter. The nucleotide sequence of the F1 promoter is shown in SEQ ID NO:13. The nucleotide sequence of the T7 promoter is shown in SEQ ID NO:78.

[0031] As the promoter, a highly active promoter of a conventional promoter may be obtained and used by using various reporter genes. For example, the activity of the promoter can be increased by making the -35 and -10 regions in the promoter region closer to the consensus sequence (WO00 / 18935). Examples of highly active promoters include various tac-like promoters (Katashkina JI et al. Russian Federation Patent application 2006134574) and pnlp8 promoter (WO2010 / 027045). Methods for evaluating promoter strength and examples of strong promoters are described in Goldstein et al.'s paper (Prokaryotic promoters in biotechnology. Biotechnol. Annu. Rev., 1, 105-128 (1995)).

[0032] The promoter may be, for example, a promoter having the nucleotide sequence of the promoter exemplified above (for example, the nucleotide sequences of SEQ ID NO: 13 and 78). The promoter may also be a conservative variant of the nucleotide sequence of the promoter exemplified above (for example, the nucleotide sequences of SEQ ID NO: 13 and 78). That is, for example, the promoter exemplified above can be used as is or after appropriate modification. The promoters specified by the promoter names above include the promoters exemplified above, as well as their conservative variants. For example, the term "F1 promoter" includes the promoter having the nucleotide sequence of SEQ ID NO: 13, as well as its conservative variants. For example, the term "T7 promoter" includes the promoter having the nucleotide sequence of SEQ ID NO: 78, as well as its conservative variants. The description of the conservative variant of the ribonuclease III gene described below can be applied mutatis mutandis to the conservative variant of the promoter. For example, the promoter may be a promoter having a nucleotide sequence with 80% or more, preferably 90% or more, more preferably 95% or more, even more preferably 97% or more, and particularly preferably 99% or more homology to the nucleotide sequence of SEQ ID NO: 13 or 78, so long as the original function is maintained. The "original function" of the promoter refers to the function of expressing a gene connected immediately downstream of the promoter under a predetermined condition. "Under a predetermined condition" refers to a condition under which the original promoter can express a gene connected immediately downstream of the promoter. For example, the gene can be constitutively expressed from the F1 promoter. Also, for example, the gene can be inducibly expressed from the T7 promoter, T5 promoter, T3 promoter, or SP6 promoter in the presence of T7 RNA polymerase, T5 RNA polymerase, T3 RNA polymerase, or SP6 RNA polymerase. The conservative variant of the promoter may have, for example, 80% or more, 90% or more, or 100% or more of the transcription activity of the original promoter. The presence or absence and strength (transcription activity) of the gene expression can be confirmed, for example, using a reporter gene.

[0033] A terminator for terminating transcription of the gene can be placed downstream of the target RNA gene. The terminator is not particularly limited as long as it functions in the host. The terminator may be a terminator derived from the host or a terminator derived from a different species. The terminator may be a terminator inherent to the target RNA gene or a terminator of another gene. A specific example of the terminator is the terminator of bacteriophage BFK20.

[0034] Vectors, promoters, and terminators that can be used in various microorganisms are described in detail in, for example, "Basic Microbiology Lectures 8: Genetic Engineering, Kyoritsu Shuppan, 1987," and they can be used.

[0035] The method of introducing an expression unit of an RNA of interest into a coryneform bacterium is not particularly limited. "Introduction of an expression unit of an RNA of interest" refers to having the expression unit of an RNA of interest retained in a host, and specifically, may be to introduce an expression unit of an RNA of interest into a host so that the gene of an RNA of interest can be expressed. Unless otherwise specified, "introduction of an expression unit of an RNA of interest" is not limited to the case where a previously constructed expression unit of an RNA of interest is introduced into a host all at once, but also includes the case where at least an RNA of interest is introduced into a host and an expression unit of an RNA of interest is constructed within the host. In the bacterium of the present invention, the expression unit of an RNA of interest may be present on a vector that autonomously replicates outside a chromosome, such as a plasmid, or may be incorporated into a chromosome. That is, the bacterium of the present invention may have, for example, an expression unit of an RNA of interest on a vector, in other words, a vector containing an expression unit of an RNA of interest. The bacterium of the present invention may also have, for example, an expression unit of an RNA of interest on a chromosome. The bacterium of the present invention may have only one copy of an expression unit of an RNA of interest, or may have two or more copies of an expression unit of an RNA of interest. The copy number of the expression unit of the target RNA in the bacterium of the present invention may be, for example, 5 copies / cell or more, 10 copies / cell or more, 20 copies / cell or more, 30 copies / cell or more, 50 copies / cell or more, 70 copies / cell or more, 100 copies / cell or more, 150 copies / cell or more, 200 copies / cell or more, 300 copies / cell or more, 500 copies / cell or more, or 1000 copies / cell or more, or 2000 copies / cell or less, 1500 copies / cell or less, 1000 copies / cell or less, 500 copies / cell or less, or 300 copies / cell or less, or a compatible combination thereof. The bacterium of the present invention may have only one type of expression unit of the target RNA, or may have two or more types of expression units of the target RNA. The copy number and type of the expression unit of the target RNA may be read as the copy number and type of the target RNA gene, respectively.When the bacterium of the present invention has two or more expression units for a target RNA, the expression units may be retained in the bacterium of the present invention so as to be capable of producing the target RNA. For example, the expression units may all be retained on a single expression vector, or all may be retained on a chromosome. The expression units may also be retained separately on multiple expression vectors, or may be retained separately on a single or multiple expression vectors and on a chromosome.

[0036] The expression unit of the target RNA can be introduced into the host using, for example, a vector containing the expression unit of the target RNA. A vector containing an expression unit of the target RNA is also called an "expression vector of the target RNA". The expression vector of the target RNA can be constructed, for example, by linking the expression unit of the target RNA to a vector. In addition, for example, when the vector has a promoter that functions in coryneform bacteria, the expression vector of the target RNA can also be constructed by linking the target RNA gene downstream of the promoter. By transforming the host with the expression vector of the target RNA, a transformant into which the vector has been introduced can be obtained, that is, the expression unit of the target RNA can be introduced into the host. As the vector, a vector capable of autonomously replicating in the cells of the host can be used. The vector is preferably a multicopy vector. The copy number of the vector may be, for example, 5 copies / cell or more, 10 copies / cell or more, 20 copies / cell or more, 30 copies / cell or more, 50 copies / cell or more, 70 copies / cell or more, 100 copies / cell or more, 150 copies / cell or more, 200 copies / cell or more, 300 copies / cell or more, 500 copies / cell or more, or 1000 copies / cell or more, or 2000 copies / cell or less, 1500 copies / cell or less, 1000 copies / cell or less, 500 copies / cell or less, or 300 copies / cell or less, or any combination thereof that does not contradict. In addition, when selecting a transformant, In order to achieve this, it is preferable that the vector has a marker such as an antibiotic resistance gene or an auxotrophy complementing gene. The vector may also have a promoter or a terminator for expressing the inserted gene. The vector may be, for example, a bacterial plasmid-derived vector, a yeast plasmid-derived vector, a bacteriophage-derived vector, a cosmid, or a phagemid. Specific examples of vectors capable of autonomous replication in coryneform bacteria include pHM1519 (Agric. Biol. Chem., 48, 2901-2903(1984)); pAM330 (Agric. Biol. Chem., 48, 2902-2903(1985)); 2901-2903 (1984); improved plasmids carrying drug resistance genes; pCRY30 (JP Patent Publication No. 3-210184); pCRY21, pCRY2KE, pCRY2KX, pCRY31, pCRY3KE, and pCRY3KX (JP Patent Publication No. 2-72876, U.S. Pat. No. 5,185,262); pCRY2 and pCRY3 (JP Patent Publication No. 1-191686); pAJ655, pAJ611, and pAJ1844 (JP Patent Publication No. 1983) -192900); pCG1 (JP 57-134500); pCG2 (JP 58-35197); pCG4 and pCG11 (JP 57-183799); pPK4 (U.S. Pat. No. 6,090,597); pVK4 (JP 9-322774); pVK7 (JP 10-215883); pVK9 (US 2006-0141588); pVC7 (JP 9-070291); and pVS7 (WO 2013 / 069634). Specific examples of vectors capable of autonomous replication in coryneform bacteria include pVC7 variants, such as pVC7H1, pVC7H2, pVC7H3, pVC7H4, pVC7H5, pVC7H6, and pVC7H7 (all of which are described in the Examples of the present application), and pPK4 variants, such as pPK4H1, pPK4H2, pPK4H3, pPK4H4, pPK4H5, and pPK4H6 (all of which are described in the Examples of the present application).

[0037] The expression unit of the target RNA can also be introduced onto the host chromosome using a transposon such as an artificial transposon. When a transposon is used, the expression unit of the target RNA is introduced onto the chromosome by homologous recombination or its own transposition ability. The expression unit of the target RNA can also be introduced onto the host chromosome by other methods using homologous recombination. Examples of the introduction method using homologous recombination include a method using linear DNA, a plasmid containing a temperature-sensitive replication origin, a conjugatively transferable plasmid, or a suicide vector that does not have a replication origin that functions in the host. Only one copy of the expression unit of the target RNA may be introduced, or two or more copies may be introduced. For example, multiple copies of the expression unit of the target RNA can be introduced into the chromosome by performing homologous recombination targeting a sequence that has multiple copies on the chromosome. Examples of sequences that have multiple copies on the chromosome include repetitive DNA sequences and inverted repeats that exist at both ends of a transposon. Alternatively, at least the target RNA gene may be introduced onto the chromosome, and the expression unit of the target RNA may be constructed on the chromosome. For example, an expression unit of an RNA of interest can be constructed on a chromosome by introducing the RNA of interest downstream of a promoter sequence on a chromosome of a host. Note that introduction of a part of the expression unit of an RNA of interest, such as an RNA of interest gene, into a chromosome can be carried out in the same manner as introduction of the whole expression unit of an RNA of interest into a chromosome.

[0038] The method of transformation is not particularly limited, and commonly used methods such as the protoplast method (Gene, 39, 281-286 (1985)), electroporation method (Bio / Technology, 7, 1067-1070 (1989)), and electric pulse method (JP Patent Publication No. 2-207791) can be used.

[0039] <1-3> Reduction in ribonuclease III activity The bacterium of the present invention has been modified to reduce ribonuclease III (RNase III) activity. Specifically, the bacterium of the present invention has been modified to reduce ribonuclease III activity compared to a non-modified strain. The ribonuclease III activity may be reduced to, for example, 50% or less, 20% or less, 10% or less, 5% or less, or 0% of that of a non-modified strain. That is, the bacterium of the present invention may be modified, for example, to lack (eliminate) ribonuclease III activity. By modifying a coryneform bacterium to reduce ribonuclease III activity, the ability of the bacterium to produce a target RNA can be improved, that is, the production of a target RNA by the bacterium can be increased.

[0040] The ribonuclease III and the gene encoding it are described below.

[0041] "RIbonuclease III" refers to a protein that has the activity of catalyzing a reaction that cleaves specific RNA such as double-stranded RNA. The gene that encodes RIbonuclease III is also called "RIbonuclease III gene."

[0042] An example of the ribonuclease III gene is the rnc gene. The protein (ribonuclease III) encoded by the rnc gene is also called the "Rnc protein."

[0043] The nucleotide sequence of the ribonuclease III gene such as the rnc gene possessed by coryneform bacteria and the amino acid sequence of the ribonuclease III such as the Rnc protein encoded thereby can be obtained, for example, from a public database such as NCBI (National Center for Biotechnology Information). The nucleotide sequence of the rnc gene of the C. glutamicum ATCC 13869 strain and the amino acid sequence of the Rnc protein encoded by the same gene are shown in SEQ ID NOs: 51 and 52, respectively. That is, the ribonuclease III gene may be, for example, a gene having the nucleotide sequence of the ribonuclease III gene exemplified above (for example, the nucleotide sequence shown in SEQ ID NO: 51). Furthermore, the ribonuclease III may be, for example, a protein having the amino acid sequence of the ribonuclease III exemplified above (for example, the amino acid sequence shown in SEQ ID NO: 52). The phrase "a gene or protein has a nucleotide sequence or an amino acid sequence" means that the gene or protein contains the nucleotide sequence or the amino acid sequence, unless otherwise specified, and also includes the case where the gene or protein consists of the nucleotide sequence or the amino acid sequence.

[0044] The RNase III gene may be a variant of the above-exemplified RNase III gene (e.g., a gene having the base sequence shown in SEQ ID NO: 51) so long as the original function is maintained. Similarly, the RNase III may be a variant of the above-exemplified RNase III (e.g., a protein having the amino acid sequence shown in SEQ ID NO: 52) so long as the original function is maintained. Such a variant that maintains the original function may be referred to as a "conservative variant". In the present invention, the term "rnc gene" is not limited to the above-exemplified rnc genes and includes conservative variants thereof. Similarly, the term "Rnc protein" is not limited to the above-exemplified Rnc proteins and includes conservative variants thereof. Examples of conservative variants include homologs and artificially modified versions of the above-exemplified RNase III genes and RNase III.

[0045] "Maintaining the original function" means that a gene or protein variant has a function (activity or property) corresponding to the function (activity or property) of the original gene or protein. That is, in the case of the RNase III gene, "maintaining the original function" means that the gene variant encodes a protein that maintains the original function (i.e., a protein that has RNase III activity). Also, in the case of RNase III, "maintaining the original function" means that the protein variant has RNase III activity.

[0046] Ribonuclease III activity can be measured by incubating the enzyme with its substrate RNA (e.g., double-stranded RNA) and measuring the enzyme-dependent cleavage of the RNA. Specifically, the activity of ribonuclease III is usually measured as follows (Methods Enzymol. 2001;342:143-58.). One example is as follows: 3 This method involves adding an enzyme (e.g., a crude cell extract or a partially purified enzyme thereof) to a synthetic substrate (double-stranded state) of H-labeled poly(AU), reacting at 35°C, treating the reaction solution with trichloroacetic acid, and measuring the degree of decrease in radioactivity in the precipitate fraction (containing high molecular weight nucleic acids) over the reaction time. The activity of ribonuclease III can be calculated by using the degree of reduction in radioactivity as an indicator of substrate cleavage. 32In this method, double-stranded RNA radioactively labeled with P is added to a reaction solution containing the enzyme (30 mM Tris-HCl (pH 8.0), 250 mM potassium glutamate or 160 mM NaCl, 5 mM spermidine, 0.1 mM EDTA, 0.1 mM DTT) and incubated at 37°C for 5 minutes. The RNA degradation reaction is started by adding MgCl2 to a final concentration of 10 mM. After the reaction has progressed appropriately, an equal volume of EDTA-electrophoresis marker dye mixture (a concentration that results in a final EDTA concentration of 20 mM or more) is added to stop the reaction. The reaction sample is then subjected to electrophoresis using a 15% (w / v) denaturing polyacrylamide gel in TBE buffer (89 mM Tris / Tris-borate, 2 mM EDTA) containing 7 M urea, and the gel is subjected to a radiographic image analyzer to analyze the degraded RNA fragments, thereby detecting RNase III activity.

[0047] Examples of conservative variants are given below.

[0048] Homologs of RNase III genes or RNase III homologs can be easily obtained from public databases, for example, by BLAST or FASTA search using the nucleotide sequence of the RNase III gene or the amino acid sequence of the RNase III as a query sequence. Homologs of RNase III genes can also be obtained, for example, by PCR using the chromosome of a coryneform bacterium as a template and oligonucleotides prepared based on the nucleotide sequence of these known RNase III genes or their surrounding regions as primers.

[0049] As long as the original function is maintained, the ribonuclease III gene may be a gene encoding a protein having an amino acid sequence in which one or several amino acids at one or several positions in the amino acid sequence of the ribonuclease III exemplified above (for example, the amino acid sequence shown in SEQ ID NO: 52) have been substituted, deleted, inserted, and / or added. Note that the above-mentioned "one or several" varies depending on the position of the amino acid residue in the three-dimensional structure of the protein and the type of amino acid residue, and specifically means, for example, 1 to 50, 1 to 40, 1 to 30, preferably 1 to 20, more preferably 1 to 10, even more preferably 1 to 5, and particularly preferably 1 to 3.

[0050] The above-mentioned substitution, deletion, insertion, and / or addition of one or several amino acids is a conservative mutation that maintains the normal function of the protein. A representative conservative mutation is a conservative substitution. A conservative substitution is a mutation in which Phe, Trp, and Tyr are substituted with each other when the substitution site is an aromatic amino acid, Leu, Ile, and Val are substituted with each other when the substitution site is a hydrophobic amino acid, Gln and Asn are substituted with each other when the substitution site is a polar amino acid, Lys, Arg, and His are substituted with each other when the substitution site is a basic amino acid, Asp and Glu are substituted with each other when the substitution site is an acidic amino acid, and Ser and Thr are substituted with each other when the substitution site is an amino acid having a hydroxyl group. Specific examples of substitutions that are considered to be conservative substitutions include substitutions of Ala to Ser or Thr, substitutions of Arg to Gln, His, or Lys, substitutions of Asn to Glu, Gln, Lys, His, or Asp, substitutions of Asp to Asn, Glu, or Gln, substitutions of Cys to Ser or Ala, substitutions of Gln to Asn, Glu, Lys, His, Asp, or Arg, substitutions of Glu to Gly, Asn, Gln, Lys, or Asp, substitutions of Gly to Pro, substitutions of His to Asn, Lys, Gln, Arg, or Tyr, substitutions of Il Examples of such substitutions include substitutions of Lys with Leu, Met, Val, or Phe, substitutions of Leu with Ile, Met, Val, or Phe, substitutions of Lys with Asn, Glu, Gln, His, or Arg, substitutions of Met with Ile, Leu, Val, or Phe, substitutions of Phe with Trp, Tyr, Met, Ile, or Leu, substitutions of Ser with Thr or Ala, substitutions of Thr with Ser or Ala, substitutions of Trp with Phe or Tyr, substitutions of Tyr with His, Phe, or Trp, and substitutions of Val with Met, Ile, or Leu. The above-mentioned amino acid substitutions, deletions, insertions, or additions also include those that occur due to naturally occurring mutations (mutants or variants) based on individual differences or species differences in the bacteria from which the genes are derived.

[0051] In addition, the RNase III gene may be used in any of the above-mentioned embodiments as long as its original function is maintained. It may be a gene encoding a protein having an amino acid sequence that has a homology of 80% or more, preferably 90% or more, more preferably 95% or more, even more preferably 97% or more, and particularly preferably 99% or more to the entire amino acid sequence of ribonuclease III. In this specification, "homology" means "identity".

[0052] Furthermore, the RNase III gene may be a DNA that hybridizes under stringent conditions with a complementary sequence of the nucleotide sequence of the above-exemplified RNase III gene (e.g., the nucleotide sequence shown in SEQ ID NO: 51) or a probe that can be prepared from the complementary sequence, so long as the original function is maintained. "Stringent conditions" refer to conditions under which so-called specific hybrids are formed and non-specific hybrids are not formed. One example of such a condition includes conditions under which DNAs with high homology, for example, DNAs with a homology of 80% or more, preferably 90% or more, more preferably 95% or more, even more preferably 97% or more, and particularly preferably 99% or more, hybridize with each other, and DNAs with lower homology than that do not hybridize with each other, or conditions for washing once, preferably 2 to 3 times, at a salt concentration and temperature equivalent to 60°C, 1 x SSC, 0.1% SDS, preferably 60°C, 0.1 x SSC, 0.1% SDS, more preferably 68°C, 0.1 x SSC, 0.1% SDS.

[0053] The above-mentioned probe may be, for example, a part of the complementary sequence of a gene. Such a probe can be prepared by PCR using oligonucleotides prepared based on the base sequence of a known gene as primers and a DNA fragment containing these base sequences as a template. For example, a DNA fragment of about 300 bp in length can be used as the probe. In such a case, washing conditions for hybridization include 50°C, 2×SSC, and 0.1% SDS.

[0054] In addition, since the degeneracy of codons differs depending on the host, the RNase III gene may be one in which any codon is replaced with an equivalent codon, i.e., the RNase III gene may be a variant of the above-mentioned RNase III genes due to the degeneracy of the genetic code.

[0055] The percentage of sequence identity between two sequences can be determined, for example, using a mathematical algorithm. Non-limiting examples of such mathematical algorithms include the algorithm of Myers and Miller (1988) CABIOS 4:11-17, the local homology algorithm of Smith et al (1981) Adv. Appl. Math. 2:482, the homology alignment algorithm of Needleman and Wunsch (1970) J. Mol. Biol. 48:443-453, the method of searching for similarity of Pearson and Lipman (1988) Proc. Natl. Acad. Sci. 85:2444-2448, and the algorithm of Karlin and Altschul (1990) Proc. Natl. Acad. Sci. USA 87:2264, with modifications as described in Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-5877.

[0056] Using programs based on these mathematical algorithms, sequence comparison (alignment) for determining sequence identity can be performed. The programs can be executed by a computer as appropriate. Such programs include, but are not limited to, CLUSTAL (available from Intelligenetics, Mountain View, Calif.) and ALIGN programs (Version 2.0) of the PC / Gene program, and GAP, BESTFIT, BLAST, FASTA, and TFASTA of the Wisconsin Genetics Software Package, Version 8 (available from Genetics Computer Group (GCG), 575 Science Drive, Madison, Wis., USA). Alignment using these programs can be performed, for example, using default parameters. The CLUSTAL program has been described in detail in Higgins et al. (1988) Gene 73:237-244, Higgins et al. (1989) CABIOS 5:151-153, Corpet et al. (1988) Nucleic Acids Res. 16:10881-90, Huang et al. (1992) CABIOS 8:155-65, and Pearson et al. (1994) Meth. Mol. Biol. 24:307-331.

[0057] To obtain nucleotide sequences that are homologous to a nucleotide sequence that encodes a protein of interest, a BLAST nucleotide search can be performed, for example, with the BLASTN program, score=100, word length=12. To obtain amino acid sequences that are homologous to a protein of interest, a BLAST protein search can be performed, for example, with the BLASTX program, score=50, word length=3. For details of BLAST nucleotide search and BLAST protein search, see http: / / www.ncbi.nlm.nih.gov. Gapped BLAST (BLAST 2.0) can also be used to obtain gapped alignments for comparison purposes. PSI-BLAST can also be used to perform iterative searches that detect distant relationships between sequences. For details of Gapped BLAST and PSI-BLAST, see Altschul et al. (1997) Nucleic Acids Res. 25:3389. When using BLAST, Gapped BLAST, or PSI-BLAST, for example, the default parameters of each program (e.g., BLASTN for nucleotide sequences, BLASTX for amino acid sequences) can be used. Alignments may also be performed manually.

[0058] The sequence identity between two sequences is calculated as the percentage of matching residues between the two sequences when the two sequences are aligned for maximum correspondence.

[0059] The above descriptions regarding gene and protein variants can also be applied mutatis mutandis to any other proteins or target RNAs, and the genes that encode them.

[0060] Below, a method for reducing the activity of a protein (enzyme) such as ribonuclease III will be described.

[0061] "The activity of a protein is reduced" means that the activity of the protein is reduced compared to that of a non-modified strain. "The activity of a protein is reduced" specifically means that the activity of the protein per cell is reduced compared to that of a non-modified strain. The "non-modified strain" as used herein means a control strain that has not been modified to reduce the activity of the target protein. Examples of non-modified strains include wild-type strains and parent strains. Examples of non-modified strains include type strains of each bacterial species. Examples of non-modified strains include the strains exemplified in the description of coryneform bacteria. That is, in one embodiment, the activity of the protein may be reduced compared to that of a type strain (i.e., a type strain of the species to which the bacterium of the present invention belongs). In another embodiment, the activity of the protein may be reduced compared to that of the C. glutamicum ATCC 13032 strain. In another embodiment, the activity of the protein may be reduced compared to that of the C. glutamicum 2256 strain (ATCC 13869). Note that "the activity of a protein is reduced" also includes a case in which the activity of the protein is completely lost. More specifically, "the activity of a protein is reduced" may mean that the number of molecules of the protein per cell is reduced and / or the function of the protein per molecule is reduced compared to a non-modified strain. That is, the "activity" in the case of "the activity of a protein is reduced" is not limited to the catalytic activity of the protein, but may mean the transcription amount (mRNA amount) or translation amount (protein amount) of a gene encoding the protein. Note that "the number of molecules of a protein is reduced per cell" also includes the case where the protein is not present at all. Furthermore, "the function of a protein per molecule is reduced" also includes the case where the function of the protein per molecule is completely lost. The degree of reduction in the activity of a protein is not particularly limited as long as the activity of the protein is reduced compared to a non-modified strain. The activity of a protein may be reduced to, for example, 50% or less, 20% or less, 10% or less, 5% or less, or 0% of that of a non-modified strain.

[0062] A modification that reduces the activity of a protein can be achieved, for example, by reducing the expression of a gene that encodes the protein. It means that the expression of the gene is decreased compared to a non-modified strain. "Decreased gene expression" specifically means that the expression level of the gene per cell is decreased compared to a non-modified strain. "Decreased gene expression" may more specifically mean that the transcription level (mRNA level) of the gene is decreased and / or the translation level (protein level) of the gene is decreased. "Decreased gene expression" also includes cases where the gene is not expressed at all. "Decreased gene expression" is also referred to as "weakened gene expression." Gene expression may be decreased to, for example, 50% or less, 20% or less, 10% or less, 5% or less, or 0% of that of a non-modified strain.

[0063] The reduction in gene expression may be due to, for example, a reduction in transcription efficiency, a reduction in translation efficiency, or a combination thereof. The reduction in gene expression can be achieved, for example, by modifying an expression regulatory sequence such as a gene promoter, a Shine-Dalgarno (SD) sequence (also called a ribosome binding site (RBS)), or a spacer region between the RBS and the start codon. When modifying an expression regulatory sequence, the expression regulatory sequence is modified preferably by one or more bases, more preferably two or more bases, and particularly preferably three or more bases. The reduction in gene transcription efficiency can be achieved, for example, by replacing a promoter of a gene on a chromosome with a weaker promoter. The term "weaker promoter" refers to a promoter that weakens the transcription of a gene compared to the wild-type promoter that is originally present. An example of a weaker promoter is an inducible promoter. That is, an inducible promoter can function as a weaker promoter under non-inducing conditions (for example, in the absence of an inducer). In addition, a part or all of the expression regulatory sequence may be deleted. In addition, the reduction in gene expression can also be achieved, for example, by manipulating factors involved in expression control. Factors involved in expression control include small molecules (inducers, inhibitors, etc.), proteins (transcription factors, etc.), and nucleic acids (siRNA, etc.) involved in transcription and translation control. Reduction of gene expression can also be achieved, for example, by introducing a mutation into the coding region of the gene that reduces the expression of the gene. For example, gene expression can be reduced by replacing a codon in the coding region of the gene with a synonymous codon that is used less frequently in the host. Furthermore, gene expression itself can be reduced, for example, by disrupting the gene as described below.

[0064] Modifications that reduce the activity of a protein can be achieved, for example, by disrupting the gene that codes for the protein. "The gene is disrupted" means that the gene is modified so that it does not produce a protein that functions normally. "Not producing a protein that functions normally" includes cases where no protein is produced from the gene at all, and cases where the gene produces a protein with reduced or lost function (activity or properties) per molecule.

[0065] The destruction of a gene can be achieved, for example, by deleting (deleting) the gene on a chromosome. "Deletion of a gene" refers to the deletion of a part or the whole region of the coding region of a gene. Furthermore, the whole gene may be deleted, including the sequences before and after the coding region of the gene on a chromosome. The region to be deleted may be any region, such as the N-terminal region (the region coding the N-terminal side of a protein), an internal region, or a C-terminal region (the region coding the C-terminal side of a protein), as long as the activity of the protein can be reduced. In general, the longer the region to be deleted, the more reliably the gene can be inactivated. The region to be deleted may be, for example, a region with a length of 10% or more, 20% or more, 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, 90% or more, or 95% or more of the entire length of the coding region of the gene. In addition, it is preferable that the sequences before and after the region to be deleted do not match in reading frame. A mismatch in reading frame may cause a frameshift downstream of the region to be deleted.

[0066] Gene disruption can also be achieved, for example, by introducing an amino acid substitution (missense mutation) into the coding region of a gene on a chromosome, introducing a stop codon (nonsense mutation), or introducing an addition or deletion of 1 to 2 bases (frameshift mutation) (Journal of Biological Chemistry 272:8611-8617(1997), Proceedings of the National Academy of Sciences, USA 95 5511-5515(1998), Journal of Biological Chemistry 26 116, 20833-20839(1991)).

[0067] Gene disruption can also be achieved, for example, by inserting another base sequence into the coding region of the gene on the chromosome. The insertion site may be any region of the gene, but the longer the base sequence to be inserted, the more reliably the gene can be inactivated. In addition, it is preferable that the sequences before and after the insertion site do not match in reading frame. A mismatch in reading frame may cause a frame shift downstream of the region to be deleted. The other base sequence is not particularly limited as long as it reduces or eliminates the activity of the encoded protein, and examples of such sequences include marker genes such as antibiotic resistance genes and genes useful for producing target substances.

[0068] The gene may be disrupted so that the amino acid sequence of the encoded protein is deleted. In other words, the modification to reduce the activity of the protein can be achieved, for example, by deleting the amino acid sequence of the protein, specifically by modifying the gene so as to code for a protein with the deleted amino acid sequence. The term "deletion of the amino acid sequence of the protein" refers to the deletion of a part or all of the region of the amino acid sequence of the protein. The term "deletion of the amino acid sequence of the protein" refers to the absence of the original amino acid sequence in the protein, and also includes the case where the original amino acid sequence is changed to another amino acid sequence. That is, for example, a region that has been changed to another amino acid sequence by frameshift may be considered as the deleted region. The deletion of the amino acid sequence of the protein typically shortens the full length of the protein, but there may be cases where the full length of the protein does not change or is extended. For example, the deletion of a part or all of the coding region of the gene can delete the region encoded by the deleted region in the encoded protein. For example, by introducing a stop codon into the coding region of a gene, the region coded by the region downstream of the introduction site can be deleted in the encoded protein. For example, by frameshifting in the coding region of a gene, the region coded by the frameshift site can be deleted in the encoded protein. The position and length of the region to be deleted in the deletion of an amino acid sequence can be determined mutatis mutandis from the explanation of the position and length of the region to be deleted in the deletion of a gene.

[0069] The above modification of a gene on a chromosome can be achieved, for example, by preparing a disrupted gene modified so as not to produce a protein that functions normally, transforming a host with recombinant DNA containing the disrupted gene, and causing homologous recombination between the disrupted gene and the wild-type gene on the chromosome, thereby replacing the wild-type gene on the chromosome with the disrupted gene. In this case, if a marker gene is included in the recombinant DNA according to the host's characteristics such as nutritional requirements, it is easy to handle in experimental operations. Examples of disrupted genes include genes in which the entire or partial region of a gene has been deleted, genes containing missense mutations, genes containing nonsense mutations, genes containing frameshift mutations, and genes into which a transposon or marker gene has been inserted. Even if a protein encoded by a disrupted gene is produced, it has a three-dimensional structure different from that of the wild-type protein, and its function is reduced or lost. Such gene disruption by gene replacement using homologous recombination has already been established, and a method called "Red-driven integration" (Datsenko, K. A, and Wanner, BL Proc. Natl. Acad. Sci. US A. 97:6640-6645 (2000)) combines the Red-driven integration method with an excision system derived from λ phage (Cho, EH, Gumport, RI, Gardner, JFJ Bacteriol. 184: 5200-5203 (2002)). These include methods that use linear DNA such as the method (see WO2005 / 010175), methods that use a plasmid containing a temperature-sensitive replication origin, methods that use a conjugatively transferable plasmid, and methods that use a suicide vector that does not have a replication origin that functions in the host (U.S. Pat. No. 6,303,383, JP-A-05-007491).

[0070] Modifications that reduce the activity of a protein may also be performed by, for example, mutation treatments, such as irradiation with X-rays, ultraviolet rays, and treatment with mutagens such as N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), ethyl methanesulfonate (EMS), and methyl methanesulfonate (MMS).

[0071] The above-mentioned methods for reducing the activity of a protein may be used alone or in any combination.

[0072] In addition, when a protein functions as a complex consisting of multiple subunits, all of the multiple subunits may be modified, or only a part of them may be modified, as long as the activity of the protein is reduced as a result. That is, for example, all of the multiple genes encoding the subunits may be disrupted, or only a part of them may be disrupted, or the like. In addition, when a protein has multiple isozymes, the activities of all of the multiple isozymes may be reduced, or only a part of them may be reduced, as long as the activity of the protein is reduced as a result. That is, for example, all of the multiple genes encoding the isozymes may be disrupted, or only a part of them may be disrupted, or the like.

[0073] The decrease in the activity of a protein can be confirmed by measuring the activity of the protein.

[0074] A decrease in protein activity can also be confirmed by confirming a decrease in expression of the gene encoding the protein. A decrease in gene expression can be confirmed by confirming a decrease in the transcription level of the gene or a decrease in the amount of the protein expressed from the gene.

[0075] The reduction in the amount of gene transcription can be confirmed by comparing the amount of mRNA transcribed from the gene with that of a non-modified strain. Methods for evaluating the amount of mRNA include northern hybridization, RT-PCR, microarrays, and RNA-seq (Molecular Cloning (Cold Spring Harbor Laboratory Press, Cold Spring Harbor (USA), 2001). The amount of mRNA (e.g., the number of mRNA molecules per cell) may be reduced to, for example, 50% or less, 20% or less, 10% or less, 5% or less, or 0% of that of a non-modified strain.

[0076] The reduction in the amount of the protein can be confirmed by Western blotting using an antibody (Molecular Cloning (Cold Spring Harbor Laboratory Press, Cold Spring Harbor (USA), 2001)). The amount of the protein (e.g., the number of protein molecules per cell) may be reduced to, for example, 50% or less, 20% or less, 10% or less, 5% or less, or 0% of that of a non-modified strain.

[0077] Depending on the means used for the disruption, gene disruption can be confirmed by determining the nucleotide sequence, restriction enzyme map, or full length of a part or all of the gene.

[0078] The above-mentioned method for reducing protein activity is not limited to reducing RNase III activity, but can be used to reduce the activity of any protein and the expression of any gene.

[0079] <2> Methods of the Invention The bacterium of the present invention obtained as described above can be used to produce a target RNA. The method of the present invention is a method for producing a target RNA, comprising culturing the bacterium of the present invention in a medium and collecting the transcribed target RNA. By culturing the bacterium of the present invention in a medium, the target RNA can be transcribed and the target RNA can be accumulated in the bacterial cells of the bacterium. That is, the method of the present invention may specifically be a method for producing a target RNA, comprising culturing the bacterium of the present invention in a medium, transcribing the target RNA, accumulating the target RNA in the bacterial cells of the bacterium, and collecting the target RNA from the bacterial cells.

[0080] The bacterium of the present invention can be cultured under culture conditions commonly used for culturing bacteria such as coryneform bacteria. The bacterium of the present invention can be cultured in a conventional medium containing, for example, a carbon source, a nitrogen source, and inorganic ions. Furthermore, organic micronutrients such as vitamins and amino acids can be added as necessary.

[0081] Examples of carbon sources that can be used include carbohydrates such as glucose and sucrose, organic acids such as acetic acid, alcohols, and others. Examples of nitrogen sources that can be used include ammonia gas, ammonia water, ammonium salts, and others. Examples of inorganic ions that can be used appropriately as needed include calcium ions, magnesium ions, phosphate ions, potassium ions, and iron ions. The culture can be carried out for 10 to 120 hours under aerobic conditions at an appropriate pH range of 5.0 to 8.5 and 15°C to 37°C. In addition, reference can be made to culture conditions for L-amino acid production by bacteria such as coryneform bacteria, and culture conditions for secretory production of proteins by bacteria such as coryneform bacteria (WO01 / 23591, WO2005 / 103278, WO2013 / 065869, WO2013 / 065772, WO2013 / 118544, WO2013 / 062029, etc.). Furthermore, when an inducible promoter is used for expressing the target RNA, the expression of the target RNA can be appropriately induced.

[0082] By culturing the bacterium of the present invention under such conditions, the target RNA is transcribed and accumulates in the cells.

[0083] The expression and accumulation of the target RNA can be confirmed, for example, by electrophoresing a fraction containing a bacterial cell extract as a sample and detecting a band corresponding to the molecular weight of the target RNA.

[0084] The target RNA can be recovered from the bacterial cells by a suitable method for separating and purifying a compound. Examples of such methods include centrifugation, salting out, ethanol precipitation, ultrafiltration, gel filtration chromatography, ion exchange chromatography, affinity chromatography, and electrophoresis. These methods may be used alone or in appropriate combination. Specifically, for example, the bacterial cells are disrupted by ultrasonic waves or the like, and the bacterial cells are removed by centrifugation or the like, from which the target RNA can be recovered by an ion exchange resin method or the like. The target RNA to be recovered may be in the free form, a salt thereof, or a mixture thereof. The target RNA to be recovered may also be a complex with a polymeric compound such as a protein. That is, the term "target RNA" in the present invention may mean the target RNA in the free form, a salt thereof, a complex thereof with a polymeric compound such as a protein, or a mixture thereof. Examples of salts include ammonium salts and sodium salts.

[0085] The recovered target RNA may contain components other than the target RNA, such as bacterial cells, medium components, moisture, and metabolic by-products of bacteria. The target RNA may be purified to a desired degree. The purity of the recovered target RNA may be, for example, 30% (w / w) or more, 50% (w / w) or more, 70% (w / w) or more, 80% (w / w) or more, 90% (w / w) or more, or 95% (w / w) or more. EXAMPLES

[0086] The present invention will be described in more detail below with reference to examples, but the present invention is not limited thereto.

[0087] <1> Isolation of a mutant lacking the ribonuclease III gene from Corynebacterium glutamicum A disruptant of the ribonuclease III (RNase III) homologue gene (hereinafter also referred to as "rnc gene") of C. glutamicum strain 2256 (ATCC13869 strain, hereinafter also referred to as "strain 2256") was constructed by the following procedure.

[0088] First, based on the amino acid sequence homology with known RNase III, we presumed that the region present in REGION: 2115207..2115950 in the genome sequence information (Accession No. AP017557) of C. glutamicum strain 2256 in the gene database (GenBank) was the rnc gene. Therefore, we obtained the ORF (open reading frame) region and the DNA base sequence information of about 1,000 bases (1 kb) of its upstream and downstream regions from the gene database (GenBank) as information necessary for deleting the gene.

[0089] Next, genomic DNA was obtained from the 2256 strain using DNeasy Blood & Tissue Kit (QIAGEN). Using this genomic DNA as a template, a DNA fragment containing about 1 kb of the upstream region of the rnc gene was amplified using primers of SEQ ID NO: 1 and 2, and a DNA fragment containing about 1 kb of the downstream region of the rnc gene was amplified using primers of SEQ ID NO: 3 and 4 with PrimeSTAR GXL DNA Polymerase (TAKARA BIO). The PCR conditions were in accordance with the manufacturer's recommended protocol. These DNA fragments were then ligated to the plasmid pBS4S (WO2005 / 113745 and WO2005 / 113744; not replicable in C. glutamicum) carrying the sacB gene in the following manner. Specifically, pBS4S was used as a template, and primers of SEQ ID NO: 5 and 6 were used to amplify the DNA using PrimeSTAR GXL DNA Polymerase. Polymerase was used for PCR amplification to obtain the amplified fragment of pBS4S. Next, both the upstream and downstream DNA fragments of the rnc gene obtained above were mixed with the amplified fragment of pBS4S, and the mixture was incubated with In-Fusion HD The three fragments were ligated using a Cloning Kit (Clontech) (Fig. 1). Competent cells of Escherichia coli JM109 strain (TAKARA BIO) were transformed with the reaction mixture, spread on LB agar medium containing 25 μg / ml kanamycin, and cultured overnight at 37°C. A single colony was then isolated from the colonies that appeared on the agar medium, and a kanamycin-resistant transformant was obtained. Plasmids were extracted from the resulting transformant by standard methods. A plasmid containing DNA fragments of the upstream and downstream regions of the rnc gene was identified by structural analysis and named pBS4SΔrnc (Fig. 1).

[0090] Since this plasmid cannot replicate autonomously in coryneform bacteria, when this plasmid is introduced into coryneform bacteria, the plasmid is integrated into the chromosome by genetic homologous recombination, and transformants that show kanamycin resistance appear, although at very low frequency. Therefore, the 2256 strain was transformed with a high concentration of the plasmid pBS4Δrnc by the electric pulse method, and the transformed strain was spread on CM-Dex agar medium (glucose 5g / L, polypeptone 10g / L, yeast extract 10g / L, KH2PO41g / L, MgSO4·7H2O 0.4g / L, FeSO4·7H2O 0.01g / L, MnSO4·7H2O 0.01g / L, urea 3g / L, soybean hydrolysate 1.2g / L, pH 7.5 (adjusted with KOH), agar 20g / L) containing 25μg / ml of kanamycin, and cultured at 30℃ overnight. As a result, several colonies appeared. The strain that grew on this medium was a so-called single-recombination strain, in which the kanamycin resistance gene and sacB gene derived from the plasmid had been inserted into the genome as a result of homologous recombination between a DNA sequence fragment near the rnc gene of the plasmid (upstream or downstream region) and a region near the rnc gene on the genome of the 2256 strain.

[0091] Next, these single recombinants were cultured overnight at 30°C in CM-Dex medium without kanamycin (same composition as CM-Dex agar medium except that it does not contain agar). The culture solution was appropriately diluted and then cultured on Dex-S10 agar medium containing 10% (w / v) sucrose without kanamycin (sucrose 100 g / L, polypeptone 10 g / L, yeast extract 10 g / L, KH2PO4 1 g / L, MgSO4 The mixture was spread on agar (0.4g / L FeSO4·7H2O, 0.01g / L FeSO4·7H2O, 0.01g / L MnSO4·4H2O, 3g / L urea, 1.2g / L soybean hydrolysate, 10μg / L biotin, pH7.5 (adjusted with KOH), 20g / L agar) and cultured overnight at 30℃. As a result, several colonies appeared. These strains were considered to be strains that had become sucrose insensitive due to the loss of the sacB gene by the second homologous recombination. The strains obtained in this way included those in which the rnc gene had been replaced by a defective type and those that had reverted to the wild type. The colonies that appeared were then subjected to colony PCR using a KOD FX NEO (TOYOBO) to select strains that had the rnc gene deleted. The length of the rnc gene region of these strains was analyzed by PCR amplification using primers of SEQ ID NO: 7 and 8. As a result, it was found that the length of the DNA fragment in PCR amplification was shorter than that of the genomic DNA of the 2256 strain (wild type) used as a template. Therefore, one of the strains was selected as an rnc gene-deficient strain and named 2256Δrnc. The length of the PCR-amplified DNA fragment in the case of the wild-type rnc gene was about 3 kbp, and the length of the PCR-amplified DNA fragment in the case of the defective rnc gene was about 2 kbp (Figure 2).

[0092] <2> Curing of endogenous plasmids The 2256 strain has an endogenous plasmid, pAM330 (Yamaguchi, Ryuji, et al. "Determination of the complete nucleotide sequence of Brevibacterium lactofermentum plasmid pAM330"). pAM330 and analysis of its genetic information." Agricultural and biological chemistry 50.11 (1986): 2771-2778.) A plasmid pVC7-sacB carrying the sacB gene was constructed from the plasmid pVC7 (JP Patent Publication 1997-070291). pVC7 is a composite plasmid of pAM330 and pHSG399 (TAKARA BIO), a general-purpose vector for Escherichia coli. Specifically, pBS4S was used as a template, and primers of SEQ ID NOs: 9 and 10 were used to amplify the sacB gene using PrimeSTAR GXL DNA PCR. Polymerase was used for PCR amplification to obtain an amplified fragment of the sacB gene. In addition, pVC7 was used as a template, and primers of SEQ ID NO:11 and SEQ ID NO:12 were used for PCR amplification using KOD FX NEO (TOYOBO) to obtain an amplified fragment of pVC7. Both amplified fragments were mixed and ligated to each other using In-Fusion HD Cloning Kit (Clontech). Next, this reaction solution was used to transform competent cells of Escherichia coli JM109 strain (TAKARA BIO), which were then spread on LB agar medium containing 25 μg / ml of chloramphenicol and cultured overnight at 37 °C. A single colony was then isolated from the colonies that appeared. Plasmids were extracted from the transformants obtained in this way by standard methods, and the desired plasmid was confirmed by DNA sequence analysis, and named pVC7-sacB (Figure 3). pVC7-sacB was introduced into the 2256 and 2256Δrnc strains by the electric pulse method, and the strains were spread on CM-Dex agar medium containing 5 μg / ml chloramphenicol and cultured overnight at 30 ° C., and several transformants of the 2256 / pVC7-sacB and 2256Δrnc / pVC7-sacB strains were obtained. Then, from among them, the 2256ΔpAM330 / pVC7-sacB strain and the 2256ΔrncΔpAM330 / pVC7-sacB strain in which the endogenous plasmid pAM330 had been removed were obtained. Furthermore, these strains were spread on Dex-S10 agar medium and cultured overnight at 30 ° C., and the 2256ΔpAM330 strain and the 2256ΔrncΔpAM330 strain in which pVC7-sacB had been removed and which had become sucrose insensitive were obtained.

[0093] <3> Construction of plasmid pVC7-Pf1-U1Ainsert for unidirectional transcription The plasmid pVC7-Pf1-U1Ainsert for unidirectional transcription of the U1A binding sequence as the target RNA under the control of the F1 promoter was constructed as follows.

[0094] The promoter sequence derived from bacteriophage BFK20, which infects coryneform bacteria (Accession No. The promoter region (SEQ ID NO: 13; hereafter referred to as F1 promoter; Koptides, M., et al., (1992). Characterization of bacteriophage BFK20 from Brevibacterium flavum. Microbiology, 138(7), 1387-1391.) and the terminator (ter) region (SEQ ID NO: 14; Bukovska, G., et al., (2006). Complete nucleotide sequence and genome analysis of bacteriophage BFK20-a lytic phage of the industrial producer Brevibacterium flavum. Virology, 348(1), 57-71) of the target RNA were added to the siRNA. The siRNA was further added to the siRNA. The siRNA was further added to the siRNA. The siRNA was further added to the siRNA. Mediate d by a cell-permeant RNA-binding protein and photoinduced RNA interference. Bioconjugate chemistry, 19(5), 1017-1024.) was selected, and the DNA sequence of the transcription unit of the U1A binding sequence (U1Ainsert RNA transcription unit; SEQ ID NO: 16) was designed (Figure 4). A DNA fragment of the U1Ainsert RNA transcription unit was prepared by chemical synthesis (Eurofin Genomics). Next, the DNA fragment was used as a template and primers SEQ ID NO: 17 and 18 were used for PCR amplification with KOD FX NEO (TOYOBO) to obtain an amplified fragment of the U1Ainsert RNA transcription unit. In addition, pVC7 was used as a template and primers SEQ ID NO: 19 and 20 were used for PCR amplification with KOD FX NEO (TOYOBO) to obtain an amplified fragment of pVC7. These amplified fragments were then mixed and ligated to each other using the In-Fusion HD Cloning Kit (Clontech). Next, the reaction solution was used to transform competent cells of Escherichia coli JM109 strain (TAKARA BIO), which were then spread onto LB agar medium containing 25 μg / ml chloramphenicol and cultured overnight at 37°C. A single colony was then isolated from the colonies that emerged to obtain a transformant. Plasmids were extracted from the resulting transformant by standard methods. The desired plasmid was identified by DNA sequence analysis and named pVC7-Pf1-U1Ainsert (Figure 4).

[0095] <4> Construction of plasmid pVC7-Pf1-Hv-iap-Pf1rev for bidirectional transcription The plasmid pVC7-Pf1-Hv-iap-Pf1rev for bidirectional transcription of Hv-iap RNA as the target RNA under the control of the F1 promoter was constructed as follows.

[0096] A DNA fragment of Hv-iap (SEQ ID NO: 21), which is a partial sequence of cDNA derived from the iap gene encoding the apoptosis inhibitor IAP derived from Coccinellidae 2010, was prepared by chemical synthesis based on the information described in WO2010 / 140675. Then, a plasmid containing a DNA sequence in which the Hv-iap sequence was linked immediately after the F1 promoter was constructed as follows (FIG. 5A). First, pVC7 was used as a template, and primers SEQ ID NO: 20 and 22 were used to amplify by PCR using KOD FX NEO (TOYOBO) to obtain a DNA fragment of pVC7. In addition, a DNA fragment of SEQ ID NO: 16 was used as a template, and primers SEQ ID NO: 23 and 24 were used to amplify by PCR using PrimeSTAR HS (TAKARA BIO) to obtain a DNA fragment containing the F1 promoter sequence. In addition, a DNA fragment of SEQ ID NO: 21 was used as a template, and primers SEQ ID NO: 25 and 26 were used to amplify by PCR using PrimeSTAR HS (TAKARA BIO) to obtain a DNA fragment of the Hv-iap sequence. These three fragments were mixed and the DNA fragments were ligated using an In-Fusion HD Cloning Kit (Clontech). Next, this reaction solution was used to transform competent cells of Escherichia coli JM109 strain (TAKARA BIO) to obtain a strain resistant to 25 μg / ml of chloramphenicol. Plasmids were extracted from the resulting transformants by standard methods. The plasmids of interest were identified by DNA sequence analysis, and one of them was named pVC7-Pf1-Hv-iap (Figure 5A).

[0097] Using pVC7 as a template, primers of SEQ ID NO:20 and 27 were used to amplify the DNA fragment of pVC7 using KOD FX NEO (TOYOBO). In addition, using the DNA fragment of SEQ ID NO:16 as a template, primers of SEQ ID NO:28 and 29 were used to amplify the DNA fragment of F1 promoter sequence using PrimeSTAR HS (TAKARA BIO). Both amplified fragments were mixed and ligated using In-Fusion HD Cloning Kit (CLONTECH). Next, competent cells of Escherichia coli JM109 strain (TAKARA BIO) were transformed with this reaction solution, spread on LB agar medium containing 25 μg / ml of chloramphenicol, and cultured overnight at 37 °C. Then, a single colony was isolated from the colonies that appeared. Plasmids were extracted from the obtained transformants by the usual method. The target plasmid was identified by DNA sequence analysis and named pVC7-Pf1rev (Figure 5B).

[0098] Next, in order to introduce the restriction enzyme sites KpnI and XhoI downstream of the F1 promoter of pVC7-Pf1rev, inverse PCR was performed using pVC7-Pf1rev as a template and the primers of SEQ ID NOs: 20 and 30, with the KOD-Plus-Mutagenesis Kit (TOYOBO). The amplified DNA fragment was then subjected to DpnI treatment, phosphorylation, and self-ligation to be circularized, and introduced into competent cells of Escherichia coli JM109 strain (TAKARA BIO). The cells were plated on LB agar medium containing 25 μg / ml chloramphenicol and cultured overnight at 37°C. Single colonies were then isolated from the colonies that emerged. Plasmids were extracted from the resulting transformants by standard methods. The plasmid of interest was identified by DNA sequence analysis and named pVC7-KpnI-XhoI-Pf1rev (Figure 5B).

[0099] Next, PCR was performed using primers of SEQ ID NO: 31 and 32 with PrimeSTAR HS (TAKARA BIO) with pVC7-Pf1-Hv-iap as a template to obtain a DNA fragment containing the KpnI restriction enzyme site-F1 promoter region-Hv-iap region-XhoI restriction enzyme site in this order. This DNA fragment and pVC7-KpnI-XhoI-Pf1rev were cut with the restriction enzymes KpnI and XhoI, respectively, and purified with MinElute PCR Purification Kit (QIAGEN). The two purified products were mixed and ligated to each other by ligation reaction using Ligation high Ver.2 (TOYOBO). Next, competent cells of Escherichia coli JM109 strain (TAKARA BIO) were transformed with this reaction solution to obtain a strain resistant to 25 μg / ml of chloramphenicol. Plasmids were extracted from the obtained transformants by conventional methods. The desired plasmid was identified by DNA sequence analysis and named pVC7-Pf1-Hv-iap-Pf1rev (Fig. 5B ).

[0100] <5> Production of target RNA The pVC7, pVC7-Pf1-U1Ainsert, and pVC7-Pf1-Hv-iap-Pf1rev plasmids were introduced into the C. glutamicum 2256ΔpAM330 and C. glutamicum 2256ΔrncΔpAM330 strains by electroporation, and the strains were plated on CM-Dex agar medium containing 5 μg / ml chloramphenicol and cultured overnight at 30°C. As a result, the transformants 2256ΔpAM330 / pVC7 strain, 2256ΔrncΔpAM330 / pVC7 strain, 2256ΔpAM330 / pVC7-Pf1-U1Ainsert strain, 2256ΔrncΔpAM330 / pVC7-Pf1-U1Ainsert strain, 2256ΔpAM330 / pVC7-Pf1-Hv-iap-Pf1rev strain, and 2256ΔrncΔpAM330 / pVC7-Pf1-Hv-iap-Pf1rev strain were obtained, respectively.

[0101] The colonies of each transformant obtained above were spread on CM-Dex agar medium (containing 5 μg / ml chloramphenicol) and cultured at 30°C for about 16 hours. Next, a part of the cultured bacteria was used for test tube culture. The bacteria were shake-cultured at 30°C for 24 hours in CM-Dex medium (2 ml) containing chloramphenicol (5 μg / ml). Then, 200 μl of the culture solution was treated with RNAprotect Bacteria Reagent and the supernatant was removed. Next, 225 μl of TE buffer containing 15 mg / ml lysozyme (Sigma) was added and reacted at room temperature for 30 minutes, and 25 μl of 20 mg / mL proK (TAKARA BIO) was added and reacted at room temperature for 30 minutes, and then RNA was extracted using TRIzol LS (Thermo Fisher Scientific). The extracted RNA was dissolved in 50 μl of RNase-free water to prepare a total RNA solution. The total RNA solutions obtained were subjected to total RNA analysis using Novex TBE Gels, 6% (Thermo Fisher Scientific). That is, 1 μl of each total RNA solution was applied to a gel lane, and polyacrylamide gel electrophoresis (PAGE) was performed under non-denaturing conditions.

[0102] As a result, when comparing the total RNA extracted from the 2256ΔpAM330 / pVC7-Pf1-U1Ainsert strain and the 2256ΔrncΔpAM330 / pVC7-Pf1-U1Ainsert strain, the RNA band derived from U1Ainsert was confirmed at the expected position only in the strain lacking the rnc gene (Figure 6). Similarly, when comparing the total RNA extracted from the 2256ΔpAM330 / pVC7-Pf1-Hv-iap-Pf1rev strain and the 2256ΔrncΔpAM330 / pVC7-Pf1-Hv-iap-Pf1rev strain, the RNA band derived from Hv-iap was confirmed at the expected position only in the strain lacking the rnc gene (Figure 6). Therefore, it was shown that the deletion of the rnc gene is effective for RNA production using Corynebacterium bacteria.

[0103] <6> Obtaining high copy number plasmids Sixty clones of 2256 / pVC7 transformants were cultured overnight in CM-Dex medium containing chloramphenicol (5 μg / ml). 500 μl of the culture medium was centrifuged (14,400 × g, 2 min) to recover the cells, which were then immersed in 100 mL of lysozyme (Sigma Aldrich) derived from chicken egg white dissolved at 15 mg / ml in P1 buffer (Qiagen). Then, 200 μl of 100% ethanol (manufactured by Qiagen) was added and reacted at 37°C for 30 minutes. Then, the plasmid was extracted from the cells of each clone using QIAprep Spin Miniprep Kit (manufactured by Qiagen) and subjected to agarose electrophoresis to compare the amount of plasmid. As a result, it was observed that the plasmid extracted from one clone showed a DNA band that was clearly thicker than those extracted from the other clones. Therefore, the plasmid was introduced again into the 2256 strain, and the plasmid was similarly extracted from the transformant, and the yield was analyzed by agarose electrophoresis. As above, the plasmid showed a DNA band that was clearly thicker than the control pVC7, that is, it was revealed that the plasmid was maintained at a higher copy number in the cells of the coryneform bacteria than the original plasmid pVC7. This plasmid was named pVC7H1.

[0104] The mutation site of the obtained pVC7H1 was analyzed using a DNA sequencer Genetic Analyzer 3500xl (Applied Biosystems). As a result, it was revealed that in pVC7H1, the 1172nd base (the second base A from the 5' end of the cleavage recognition site of the restriction enzyme HindIII is +1) of the total base sequence of pVC7 (6679 bp) was substituted from cytosine (C) to adenine (A). Hereinafter, this mutation will be referred to as "C1172A". Therefore, it was revealed that this mutation is the cause of the high copy number of pVC7H1.

[0105] Since it was revealed that the C1172A mutation significantly increased the copy number of pVC7, the mutations in this region listed in Table 1 were each introduced into pVC7 to evaluate their effect on the copy number of the plasmid.

[0106] Each mutant plasmid was constructed using KOD-Plus-Mutagenesis Kit (manufactured by Toyobo Co., Ltd.). Using plasmid pVC7 as a template, pVC7H2 was constructed using primers of SEQ ID NO: 33 and 34, pVC7H3 was constructed using primers of SEQ ID NO: 33 and 35, pVC7H4 was constructed using primers of SEQ ID NO: 36 and 37, pVC7H5 was constructed using primers of SEQ ID NO: 36 and 38, pVC7H6 was constructed using primers of SEQ ID NO: 33 and 39, and pVC7H7 was constructed using primers of SEQ ID NO: 33 and 40 (Table 1). The entire nucleotide sequence was confirmed to be correct using a DNA sequencer.

[0107] [Table 1]

[0108] Each constructed plasmid was transformed into the 2256ΔpAM330 strain by a standard method. CM-Dex agar medium containing chloramphenicol (5 μg / ml) was used as the selection medium. When any plasmid was transformed, colonies were formed well. Therefore, colonies carrying each plasmid were inoculated into the same agar medium using a platinum loop and cultured at 30°C for about one day. Then, the grown bacterial bodies (approximately 2 cm square) of each strain were inoculated into CM-Dex medium containing chloramphenicol (5 mg / L) and cultured overnight with shaking at 30°C.

[0109] The plasmids contained in the culture were extracted from the culture medium by a standard method. A portion of the prepared plasmid solution was subjected to agarose electrophoresis, and the DNA bands of each plasmid were analyzed. The results are shown in Table 2.

[0110] [Table 2]

[0111] As a result, mutant plasmids with a clearly higher copy number than the initially obtained pVC7H1 were obtained. One of them, pVC7H2, was used in the subsequent experiments. The copy number of pVC7 is thought to be about 10 copies / cell, that of pVC7H1 about 100 copies / cell, and that of pVC7H2 about 250 copies / cell.

[0112] <7> RNA production using high copy number plasmids High copy number versions of pVC7-Pf1-U1Ainsert and pVC7-Pf1-Hv-iap-Pf1rev were constructed by the following procedure. Specifically, pVC7-Pf1-U1Ainsert or pVC7-Pf1-Hv-iap-Pf1rev was used as a template, and primers of SEQ ID NOs: 33 and 41 for pVC7H1 mutagenesis or primers of SEQ ID NOs: 33 and 34 for pVC7H2 mutagenesis were used to construct high copy number versions of pVC7-Pf1-U1Ainsert and pVC7-Pf1-Hv-iap-Pf1rev using the KOD-Plus-Mutagenesis Kit (TOYOBO). Inverse PCR was performed. The resulting DNA fragment was then subjected to DpnI treatment, phosphorylation, and self-ligation to cyclize it, and used to transform competent cells of Escherichia coli JM109 strain (TAKARA BIO). The cells were plated on LB agar medium containing chloramphenicol (25 μg / ml) and cultured overnight at 37°C. Single colonies were isolated from the colonies that emerged. Plasmids were extracted from the transformants by standard methods. The plasmids of interest were identified by DNA sequence analysis and named pVC7H1-Pf1-U1Ainsert, pVC7H2-Pf1-U1Ainsert, pVC7H1-Pf1-Hv-iap-Pf1rev, and pVC7H2-Pf1-Hv-iap-Pf1rev.

[0113] Next, each of the plasmids pVC7, pVC7-Pf1-U1Ainsert, pVC7H1-Pf1-U1Ainsert, pVC7H2-Pf1-U1Ainsert, pVC7-Pf1-Hv-iap-Pf1rev, pVC7H1-Pf1-Hv-iap-Pf1rev, and pVC7H2-Pf1-Hv-iap-Pf1rev was introduced into the 2256ΔrncΔpAM330 strain by the electroporation method and plated on CM-Dex agar medium containing chloramphenicol (5 μg / ml) and cultured overnight at 30°C. Thereby, the transformants 2256ΔrncΔpAM330 / pVC7 strain, 2256ΔrncΔpAM330 / pVC7-Pf1-U1Ainsert strain, 2256ΔrncΔpAM330 / pVC7H1-Pf1-U1Ainsert strain, 2256ΔrncΔpAM330 / pVC7H2-Pf1-U1Ainsert strain, 2256ΔrncΔpAM330 / pVC7-Pf1-Hv-iap-Pf1rev strain, 2256ΔrncΔpAM330 / pVC7H1-Pf1-Hv-iap-Pf1rev strain, and 2256ΔrncΔpAM330 / pVC7H2-Pf1-Hv-iap-Pf1rev strain were obtained, respectively. Then, those strains were cultured in test tubes and the RNA produced by those strains was evaluated. A part of the cells cultured on the agar medium from the colonies of each transformant was inoculated into CM-Dex medium (2 ml) containing chloramphenicol (5 μg / ml) and cultured with shaking at 30°C for 24 hours. Thereafter, RNA was extracted from 200 μl of the culture solution by the same procedure as in the above example including treatment with RNAprotect Bacteria Reagent, and finally the RNA sample was dissolved in 50 μl of RNase-free water to prepare a total RNA solution. For the obtained total RNA solution, total RNA analysis by PAGE under non-denaturing conditions using Novex TBE Gels (6%) was performed. As a result, the accumulation amount of U1Ainsert-RNA increased in the order of pVC7-Pf1-U1Ainsert << pVC7H1-Pf1-U1Ainsert ≒ pVC7H2-Pf1-U1Ainsert (Figure 7).Similarly, the accumulation amount of Hv-iap-dsRNA also increased in the order of pVC7-Pf1-Hv-iap-Pf1rev <<< pVC7H1-Pf1-Hv-iap-Pf1rev < pVC7H2-Pf1-Hv-iap-Pf1rev (Figure 7). From this, it was shown that increasing the copy number of the RNA transcription plasmid increases the intracellular accumulation amount of the target RNA.

[0114] <8>Comparison of RNA production by the T7 promoter-inducible expression system in E. coli As described previously (Timmons, L., Court, D. L., & Fire, A. (2001). Ingestion of bacterially expressed dsRNAs can produce specific and potent genetic interference in Caenorhabditis elegans. Gene, 263(1), 103-112.), an RNA production system using T7 RNA polymerase has been reported in the Escherichia coli HT115(DE3) strain, which is an rnc gene-deficient strain. Therefore, RNA production by the F1 promoter expression system in the C. glutamicum 2256ΔrncΔpAM330 strain was compared with RNA production by the T7 promoter-inducible expression system in E. coli.

[0115] For this purpose, the plasmid pL4440-Pt7-U1Ainsert for transcribing the U1A binding sequence in one direction under the control of the T7 promoter and the plasmid pL4440-Pt7-Hv-iap-Pt7rev for bidirectionally transcribing Hv-iap RNA under the control of the T7 promoter were constructed by the following procedure.

[0116] Using the plasmid pL4440 (GE Healthcare) as a template, PCR was performed using primers of SEQ ID NO: 42 and 43 on KOD FX NEO to obtain a DNA fragment of pL4440. Also, using pVC7-Pf1-U1Ainsert as a template, PCR was performed using primers of SEQ ID NO: 44 and 45 on PrimeSTAR HS (TAKARA BIO) to obtain a DNA fragment containing the U1Ainsert sequence. Also, the DNA strand of SEQ ID NO: 46 and the DNA strand of SEQ ID NO: 47 (the DNA strand of SEQ ID NO: 47 has a sequence corresponding to the complementary sequence of the DNA strand of SEQ ID NO: 46) were mixed and annealed to each other, and purified with MinElute PCR Purification Kit to obtain a DNA fragment of the T7 terminator sequence. These three DNA fragments were mixed and ligated to each other using the In-Fusion HD Cloning Kit. Next, the reaction mixture was used to transform competent cells of Escherichia coli JM109 strain, which was then spread onto LB agar medium containing ampicillin (100 μg / ml) and cultured overnight at 37°C. Single colonies were then isolated from the colonies that appeared. Plasmids were extracted from the resulting transformants by standard methods. The plasmids of interest were identified by DNA sequence analysis, and one of them was named pL4440-Pt7-U1Ainsert (Figure 8).

[0117] Using the plasmid pL4440 as a template and primers of SEQ ID NOs: 42 and 48, KOD FX PCR was performed using NEO to obtain a DNA fragment of pL4440. <9> PCR was performed using primers of SEQ ID NO: 49 and 50 with KOD FX NEO, using the template (described later in (2-2)), to obtain a DNA fragment of the "Pt7-Hv-iap-Pt7rev" region. These DNA fragments were mixed and ligated to each other using the In-Fusion HD Cloning Kit. Next, competent cells of Escherichia coli JM109 strain were transformed with this reaction solution, spread on LB agar medium containing ampicillin (100 μg / ml), and cultured overnight at 37 °C. Then, a single colony was isolated from the colonies that appeared. Plasmids were extracted from the obtained transformants by conventional methods. The target plasmids were identified by DNA sequence analysis, and one of them was named pL4440-Pt7-Hv-iap-Pt7rev (Figure 9).

[0118] pL4440-Pt7-U1Ainsert or pL4440-Pt7-Hv-iap-Pt7rev was introduced into E. coli HT115(DE3) by electric pulse method to obtain the transformants HT115(DE3) / pL4440-Pt7-U1Ainsert and HT115(DE3) / pL4440-Pt7-Hv-iap-Pt7rev. These strains were shake-cultured overnight at 37°C in LB liquid medium containing ampicillin (100 μg / ml) in a test tube to prepare seed cultures. Next, the seed culture was added to LB liquid medium containing ampicillin (100 μg / ml) at 1 / 50th the volume, and main culture was started at 37°C. After culturing with shaking for about 3 hours, IPTG was added to a final concentration of 1 mM, and the culturing was continued. Samples were taken 4 hours, 8 hours, and 24 hours after the addition of IPTG. 200 μl of the culture solution was centrifuged at 13,800×g for 2 minutes to collect the bacteria. RNA was extracted using TRIzol (Thermo Fisher Scientific) according to the protocol, and dissolved in 50 μl of RNase-free water to prepare a total RNA solution. For comparison, <7> The total RNA solution of C. glutamicum obtained in 1) was used. PAGE was performed under non-denaturing conditions using 1 μl of each RNA sample and Novex TBE Gels (6%). As a result, the amount of U1Ainsert-ssRNA produced by the F1 promoter expression system in C. glutamicum was greater than the amount of U1Ainsert-ssRNA produced by the T7 promoter-inducible expression system in E. coli (Figure 10). Similarly, the amount of Hv-iap-dsRNA produced by the F1 promoter expression system in C. glutamicum was greater than the amount of Hv-iap-dsRNA produced by the T7 promoter-inducible expression system in E. coli (Figure 10). Thus, it was revealed that coryneform bacteria such as C. glutamicum are useful for producing target RNA.

[0119] <9> RNA production using a T7 promoter-inducible expression system in C. glutamicum (1) Preparation of hairpin RNA (1-1) Construction of plasmid pPK-T7lac-vd-antiOlac for transcription of hairpin RNA The plasmid pPK-T7lac-vd-antiOlac for unidirectional transcription of a hairpin RNA as a target RNA under the control of the T7 promoter was constructed as follows.

[0120] (1-1-1) Construction of pUC57-VD Based on the genome sequence of Potato spindle tuber viroid (PSTVd).125 (Mol Biol (Mosk). 2013 Jan-Feb;47(1):94-106.), a DNA fragment of SEQ ID NO:53 encoding a hairpin RNA was prepared by chemical synthesis. This DNA fragment was cloned into pUC57 (ATG Service-Gen, St. Petersburg, Russia) to construct pUC57-VD.

[0121] (1-1-2) Construction of pPK-T7lac First, the T7 terminator (T T7 A fragment (131 bp) containing the nucleotide sequence 144 of the present invention was amplified from pET22b(+) (Novagen). This fragment was then digested with KpnI and SalI and cloned into pPK4 (US Patent 6,090,597) linearized with the same restriction enzymes. The constructed plasmid was used as pPK4XB - This was named T7 ter (Figure 11).

[0122] Next, the lacI-P T7 -Olac-MCS-T T7 Another fragment (1959 bp) containing the DNA region was amplified from pET22b(+). This amplified fragment was digested with KpnI and linearized with KpnI, pPK4 XB - The plasmid was cloned into T7 ter and named pPK-T7lac (Figure 12).

[0123] (1-1-3) Construction of pPK-T7lac-vd-antiOlac The DNA fragment VD-aOlac was excised from pUC57-VD using XbaI and XhoI and cloned into pPK-T7lac using T4 DNA ligase. The ligation mixture was transformed into competent cells of E. coli strain LE392 (Promega) by electroporation. Standard electroporation procedures for E. coli cells were performed. The cells were grown at 37°C for 1.5 h and then plated on LB agar plates supplemented with 50 μg / ml kanamycin (Km) to elucidate the kanamycin resistance (Km r ) transformants were obtained. Plasmids were extracted from the transformants, and the desired plasmid was selected and named pPK-T7lac-vd-antiOlac (Figure 13).

[0124] (1-2) Construction of plasmid pVC54-T7Pol for expressing T7 RNA polymerase The plasmid pVC54-T7Pol for expressing T7 RNA polymerase was constructed as follows.

[0125] (1-2-1) Construction of pVC54 To construct pVC54, the region of SEQ ID NO:58 of pVC7 (U.S. Patent 5,804,414) (chloramphenicol resistance (Cm r ) gene promoter region and the site derived from pAM330) was replaced with a region containing a strong promoter by the following procedure.

[0126] DNA fragment-A (161 bp) of SEQ ID NO: 58 containing a strong promoter was prepared by chemical synthesis. DNA fragment-B was amplified by PCR using primers of SEQ ID NO: 60 (L54-Cm) and 61 (R55-Cm) with pVC7 plasmid as a template. Overlapping PCR was performed using fragment-A and fragment-B, and the resulting PCR fragment was amplified again by PCR using primers of SEQ ID NO: 62 (L54-hpa) and 61 (R55-Cm) that flanked it. The amplified fragment was then cut with HpaI and NcoI and ligated into the HpaI-NcoI site of pVC7. Competent cells of E. coli strain TG1 (Zymo Research) were transformed with the ligation mixture, and Cm r Transformants were obtained. Plasmids were extracted from the transformants, and the desired plasmid was selected and named pVC54 (Figure 14).

[0127] (1-2-2) Construction of pBS5t-ptrB*-T7pol A DNA fragment (2021 bp) containing a part of the ptrB gene and a part of the hemH gene was amplified by PCR using the genomic DNA of the 2256 strain as a template and primers of SEQ ID NO: 63 (x550) and 64 (x551). The amplified fragment was digested with BglII and cloned into the BamHI site of pBS5t (WO2006 / 057450). The resulting plasmid was named pBS5t-ptrB* (Figure 15). This plasmid contains a unique NheI site in a part of the ptrB gene.

[0128] In addition, pAH162-λattL-Tc RAnother DNA fragment (531 bp) containing the rrnB terminator (TrrnB) and the L3 terminator (tL3) was amplified by PCR using primers with sequence numbers 65 (x553) and 66 (x554) with -λattR (BMC Biotechnology 2008, 8:63) as a template. The amplified fragment was cut with NheI and cloned into the NheI site of pBS5t-ptrB*. The resulting plasmid was named pBS5t-ptrB*-2Ter (Figure 16). This plasmid contains a unique BamHI site between the terminators TrrnB and tL3, and both terminators are flanked by BglII sites.

[0129] Finally, the DNA fragment (4452 bp) containing lacI-PlacUV5-gene1 was transformed into pAR1219 (Proc Natl Acad Sci US A. 1984 Apr; 81(7): 2035-2039) and pBS5t-ptrB*-2Ter The lacI-PlacUV5-gene1 fragment contains gene1, which encodes T7 RNA polymerase and is expressed under the control of the lacUV5 promoter (PlacUV5). A plasmid in which gene1 was oriented toward tL3 was selected and named pBS5t-ptrB*-T7pol (Figure 17).

[0130] (1-2-3) Construction of pVC54-T7pol The plasmid pVC54-T7Pol for expressing T7 RNA polymerase was constructed from pVC54 and pBS5t-ptrB*-T7pol as follows.

[0131] First, a DNA fragment containing lacI-PlacUV5-gene1 was excised from pBS5t-ptrB*-T7pol using BglII, and then ligated to the BamHI site of pVC54 to construct pVC54-T7pol (Figure 18).

[0132] (1-3) Construction of RNA-producing C. glutamicum First, C. glutamicum 2256ΔrncΔpAM330 was transformed with pVC54-T7Pol by electrotransformation. The cells were grown for 24 hours at 30°C in CM2G medium (5 g / L of glucose, 10 g / L of tryptone, 10 g / L of yeast extract, 5 g / L of NaCl, pH adjusted to 7.0) supplemented with 10 μg / mL chloramphenicol (Cm), and transformants were selected. Next, single colony isolation was performed to obtain two independent clones of C. glutamicum 2256ΔrncΔpAM330 carrying pVC54-T7Pol. These two clones were further transformed with pPK-T7lac-vd-antiOlac. The cells were grown for 24 hours at 30°C in CM2G medium supplemented with 10 μg / mL Cm and 25 μg / mL Km, and transformants were selected. Single colony isolation was performed again to obtain colonies of two independent clones (designated clones A and B) of C. glutamicum 2256ΔrncΔpAM330 harboring pVC54-T7Pol and pPK-T7lac-vd-antiOlac (designated C. glutamicum 2256ΔrncΔpAM330 / pVC54-T7Pol / pPK-T7lac-vd-antiOlac).

[0133] (1-4) RNA production using T7 promoter-inducible expression system in C. glutamicum C. glutamicum 2256ΔrncΔpAM330 / pVC54-T7Pol / pPK-T7lac-vd-antiOlac strains (clone A and B, respectively) were inoculated into 5 ml of CM2G medium supplemented with 10 μg / ml Cm and 25 μg / ml Km and grown overnight at 32°C. The following morning, the same strains were transferred to the same fresh medium (5 ml) to measure OD 600 The bacteria were inoculated so that the OD value was 0.2-0.3 and grown at 32°C for 4-5 hours. At this point, induction was performed by adding 2 mM IPTG to the culture. After induction, the culture was continued for an additional 3 and 19 hours, and the OD 600Then, 1–2 ml of the culture was immediately mixed with RNAprotect Bacteria Reagent (QIAGEN 76506) as recommended by the manufacturer, and the bacterial pellet was immediately frozen at −70°C.

[0134] All samples were thawed at 4°C and subjected to RNA isolation using Trizol LS (Ambion 10296028). The isolated total RNA was diluted with 30 μl of DEPC-treated water to prepare a total RNA solution, and the RNA concentration in the solution was measured using a Nanodrop spectrophotometer. A portion of the solution was then subjected to denaturing urea PAGE (5%). Typically, 3 μg of each total RNA solution was applied to a well of the gel. After electrophoresis, the RNA in the gel was stained with ethidium bromide (EthBr). As a result, the target RNA band (VD related RNAs) was observed in the sample induced with IPTG (Figure 19). In other words, RNA production by the T7 promoter-inducible expression system in C. glutamicum was confirmed.

[0135] (2) Production of Hv-iap RNA (2-1) Construction of plasmid pPK4-T7pol for expressing T7 RNA polymerase The plasmid pPK4-T7pol for expressing T7 RNA polymerase was constructed as follows.

[0136] A DNA fragment containing gene 1 (T7pol) encoding T7 RNA polymerase was generated by PCR using pVC54-T7pol as a template, primers of SEQ ID NOs: 67 and 68, and KOD FX NEO polymerase. was amplified. In addition, another DNA fragment was amplified by PCR using primers of SEQ ID NO: 69 and 70 as plasmid pPK4 (US Patent 6,090,597). Both DNA fragments were mixed and ligated to each other using In-Fusion HD Cloning Kit (TAKARA BIO). Next, competent cells of E. coli JM109 were transformed with the reaction mixture, spread on LB agar medium containing Km (50 μg / mL), and cultured at 37°C for 16 hours to obtain the Km R Transformants were obtained. Among them, several colonies were isolated, and plasmids were extracted from the transformants. After confirming the DNA sequence of the plasmid, the desired plasmid was selected and named pPK4-T7pol (Figure 20).

[0137] (2-2) Construction of plasmid pVC7-Pt7-Hv-iap-Pt7rev for transcription of Hv-iap RNA The plasmid pVC7-Pt7-Hv-iap-Pt7rev for bidirectional transcription of Hv-iap RNA as the target RNA under the control of the T7 promoter was constructed as follows.

[0138] (2-2-1) Construction of pVC7-Pt7-KpnI-XhoI-Pt7rev DNA fragment-N was amplified by PCR using primers of SEQ ID NO:71 and 72 and KOD FX NEO with pVC7 as a template. DNA fragment-P of SEQ ID NO:73 (containing T7 promoter (forward), KpnI restriction site, XhoI restriction site, and T7 promoter (reverse) in this order) and another DNA fragment-Q of SEQ ID NO:74 (containing the complementary sequence of fragment-P) were prepared by chemical synthesis, and both single-stranded DNA fragments were mixed and annealed to produce DNA fragment-R. Then, both DNA fragment-N and DNA fragment-R were ligated to each other using In-Fusion HD Cloning Kit. Competent cells of E. coli JM109 were transformed with the reaction mixture, spread on LB agar medium containing Cm (25 μg / ml), and cultured at 37°C for 16 hours to obtain Cm. RTransformants were obtained. Among them, several colonies were isolated, and plasmids were extracted from the transformants. After confirming the DNA sequence of the plasmid, the desired plasmid was selected and named pVC7-Pt7-KpnI-XhoI-Pt7rev (Figure 21).

[0139] (2-2-2) Construction of pVC7-Pt7-Hv-iap-Pt7rev DNA fragment-S (containing a KpnI restriction site, an Hv-iap site, and an XhoI restriction site, in this order) was amplified by PCR using the DNA fragment of SEQ ID NO: 75 as a template and the primers of SEQ ID NO: 76 and 77. Next, DNA fragment-S and pVC7-Pt7-KpnI-XhoI-Pt7rev were cleaved with KpnI and XhoI, respectively, and purified with a MinElute PCR Purification Kit (Qiagen). The two purified products were mixed and ligated to each other using Ligation high ver. 2 (TOYOBO). Competent cells of E. coli JM109 were transformed with the reaction mixture, spread on LB agar medium containing Cm (25 μg / ml), and cultured at 37°C for 16 hours to obtain the Cm fragment. R Transformants were obtained. Among them, several colonies were isolated, and plasmids were extracted from the transformants. After confirming the DNA sequence of the plasmid, the desired plasmid was selected and named pVC7-Pt7-Hv-iap-Pt7rev (Figure 21).

[0140] (2-3) Construction of RNA-producing C. glutamicum C. glutamicum 2256ΔrncΔpAM330 was transformed with pPK4-T7pol by electroporation. The cell suspension was spread on CM-Dex agar medium containing Km (25 μg / ml) and cultured at 30°C for 16 hours to obtain transformants. Then, pVC7-Pt7-Hv-iap-Pt7rev was introduced into one of the transformants. The cell suspension was spread on CM-Dex agar medium containing Km (25 μg / ml) and Cm (5 μg / ml) and cultured at 30°C for 24 hours to obtain transformants. Finally, C. glutamicum 2256ΔrncΔpAM330 / pPK4-T7pol / pVC7-Pt7-Hv-iap-Pt7rev was obtained.

[0141] (2-4) RNA production using T7 promoter-inducible expression system in C. glutamicum C. glutamicum 2256ΔrncΔpAM330 / pPK4-T7pol / pVC7-Pt7-Hv-iap-Pt7rev was grown in a test tube in CM-Dex medium containing Km (25 μg / ml) and Cm (5 μg / ml) at 30°C for 16 hours to prepare a seed culture. The seed culture was then added to fresh CM-Dex medium at 1 / 10 the volume, and main culture was started at 30°C. After 6 hours of culture, a portion of the culture was sampled, and 2 mM IPTG was added to the remaining portion of the culture for further culture. A portion of the culture was sampled 3 hours and 27 hours after the addition of IPTG. The above examples, including RNAprotect Bacteria Reagent treatment, were performed. RNA was extracted from 200 μl of the culture medium by the same procedure as in 1., and the RNA sample was finally diluted with 50 mL of RNase-free water. The RNA was dissolved in 1 μl of PBS to prepare a total RNA solution.

[0142] Each total RNA solution was applied to a Novex TBE gel (6%) to analyze RNA production. As a result, the target RNA band (Hv-iap RNA) was observed in the sample obtained 27 hours after IPTG induction (Figure 22). In other words, RNA production by the T7 promoter-inducible expression system in C. glutamicum was confirmed again.

[0143] <10> Obtaining high copy number plasmid of pPK4 Plasmid pPK4 is a composite plasmid of plasmid pHSG399, which is available in E. coli, and plasmid pHM1519, which is available in C. glutamicum ATCC 13058; that is, pPK4 functions as a shuttle vector capable of replicating in both bacteria (U.S. Patent 6,090,597).

[0144] Each of the mutations shown in Table 3 was introduced into pPK4, and the effect on the copy number of the plasmid was evaluated.

[0145] Each mutant plasmid was constructed using KOD-Plus-Mutagenesis Kit (manufactured by Toyobo Co., Ltd.). Using plasmid pPK4 as a template, pPK4H1 was constructed using primers of SEQ ID NO: 79 and 80, pPK4H2 was constructed using primers of SEQ ID NO: 81 and 82, pPK4H3 was constructed using primers of SEQ ID NO: 83 and 82, pPK4H4 was constructed using primers of SEQ ID NO: 84 and 82, pPK4H5 was constructed using primers of SEQ ID NO: 85 and 82, and pPK4H6 was constructed using primers of SEQ ID NO: 86 and 82 (Table 3). The entire nucleotide sequence was confirmed to be correct using a DNA sequencer.

[0146] [Table 3]

[0147] The copy number of the constructed plasmid is shown in Example <5> As a result, all of the mutant plasmids of pPK4 shown in Table 3 showed higher copy numbers in C. glutamicum than the original plasmid pPK4. Among them, pPK4H1 showed the highest copy number, reaching approximately 200 or more copies per host chromosome.

[0148] <11> RNA production using pPK4H1 The U1A-RNA expression system was incorporated into the plasmid pPK4H1 by the following procedure.

[0149] Using pVC7-Pf1-U1Ainsert as a template, an amplified fragment of the U1Ainsert RNA transcription unit was obtained by PCR amplification using primers of SEQ ID NOs: 87 and 88 and KOD FX NEO (TOYOBO). Also, using pPK4H1 as a template, an amplified fragment of pPK4H1 was obtained by PCR amplification using primers of SEQ ID NOs: 89 and 90 and KOD FX NEO (TOYOBO). These amplified fragments were mixed and ligated to each other using In-Fusion HD Cloning Kit (Clontech). Next, E. coli JM109 competent cells (TAKARA BIO) were transformed with the reaction mixture, spread on LB agar medium containing 50 μg / mL kanamycin, and cultured overnight at 37°C. Next, a single colony was isolated from the colonies that appeared to obtain a transformant. A plasmid was extracted from the obtained transformant by a conventional method. The target plasmid was identified by DNA sequence analysis and named pPK4H1-Pf1-U1Ainsert.

[0150] Plasmids pPK4H1 and pPK4H1-Pf1-U1Ainsert were introduced into C. glutamicum strain 2256ΔrncΔpAM330 by electroporation, and the resulting plasmids were plated on CM-Dex agar medium containing 25 μg / mL kanamycin and cultured overnight at 30°C to obtain the transformants 2256ΔrncΔpAM330 / pPK4H1 and 2256ΔrncΔpAM330 / pPK4H1-Pf1-U1Ainsert.

[0151] Two colonies were selected for each transformant, spread on a CM-Dex agar medium containing 25 μg / mL kanamycin, and cultured at 30°C for about 16 hours. Next, a portion of the cultured bacteria was used for test tube culture. The bacteria were shake-cultured at 30°C for 24 hours in CM-Dex medium (2 ml) containing 25 μg / mL kanamycin. Then, 200 μl of the culture solution was treated with RNAprotect Bacteria Reagent, and the supernatant was removed. Next, 225 μl of TE buffer containing 15 mg / mL lysozyme (Sigma) was added and reacted at room temperature for 30 minutes, and 25 μl of 20 mg / mL proK (TAKARA BIO) was added and reacted at room temperature for 30 minutes, and then RNA was extracted using TRIzol LS (Thermo Fisher Scientific). The extracted RNA was dissolved in 50 μl of RNase-free water to prepare a total RNA solution. The total RNA solutions obtained were subjected to total RNA analysis using Novex TBE Gels, 6% (Thermo Fisher Scientific). That is, 1 μl of each total RNA solution was applied to a gel lane, and polyacrylamide gel electrophoresis (PAGE) was performed under non-denaturing conditions.

[0152] As a result, the U1Ainsert-derived RNA band was confirmed at the expected position only in the 2256ΔrncΔpAM330 / pPK4H1-Pf1-U1Ainsert strain (FIG. 23). Therefore, even when a pHM1519-derived vector different from the pVC7-derived vector used in the previous Example was used, a large amount of target RNA could be successfully produced using Corynebacterium bacteria as a host. [Industrial Applicability]

[0153] According to the present invention, RNA can be produced efficiently.

[0154] <Description of sequence listing> SEQ ID NOs: 1 to 12: Primers SEQ ID NO: 13: Nucleotide sequence of F1 promoter SEQ ID NO: 14: Base sequence of the terminator region of BFK20 SEQ ID NO: 15: Nucleotide sequence of U1A binding sequence SEQ ID NO: 16: Nucleotide sequence of U1A insert RNA transcription unit SEQ ID NOs: 17 to 20: primers SEQ ID NO: 21: Nucleotide sequence of Hv-iap SEQ ID NOs: 22 to 50: primers SEQ ID NO: 51: Nucleotide sequence of the rnc gene of C. glutamicum 2256 (ATCC 13869) SEQ ID NO: 52: Amino acid sequence of the Rnc protein of C. glutamicum 2256 (ATCC 13869) SEQ ID NO: 53: Base sequence of DNA fragment SEQ ID NOs: 54 to 57: primers SEQ ID NO: 58: Base sequence of DNA fragment SEQ ID NO: 59: Base sequence of DNA fragment-A SEQ ID NOs: 60 to 72: primers SEQ ID NO: 73: Base sequence of DNA fragment-P SEQ ID NO: 74: Base sequence of DNA fragment-Q SEQ ID NO: 75: Base sequence of DNA fragment SEQ ID NOs: 76 to 77: primers SEQ ID NO: 78: Nucleotide sequence of T7 promoter SEQ ID NOs: 79 to 90: primers

Claims

1. A method for producing a target RNA, comprising the steps of: Cultivating a coryneform bacterium having an expression unit for a target RNA in a medium, expressing the target RNA, and accumulating the target RNA in the cells of the bacterium; and collecting target RNA from the bacterial cells; Including, The bacterium has the expression unit at a copy number of 70 copies / cell or more, The bacterium is modified so that RNase III activity is reduced compared to a non-modified strain. It has been the expression unit comprises, in the 5' to 3' direction, a promoter sequence that functions in a coryneform bacterium and a nucleotide sequence that encodes a target RNA; The method, wherein the promoter sequence is an F1 promoter or a T7 promoter.

2. The ribonuclease III is a protein selected from the group consisting of (a), (b), and (c) below: The method of claim 1, (a) a protein comprising the amino acid sequence set forth in SEQ ID NO:52; (b) an amino acid sequence comprising the amino acid sequence shown in SEQ ID NO:52, which contains a substitution, deletion, insertion, and / or addition of 1 to 10 amino acid residues, and which is an RNase III A protein having an activity; (c) a protein having an amino acid sequence having 90% or more identity to the amino acid sequence shown in SEQ ID NO:52 and having ribonuclease III activity.

3. By reducing the expression of the gene encoding RNase III or by inhibiting the expression of the gene 3. The method according to claim 1 or 2, wherein the activity of ribonuclease III is reduced by disrupting the gene. The method according to

4. The method according to any one of claims 1 to 3, wherein the activity of ribonuclease III is reduced by deleting a gene encoding ribonuclease III.

5. The bacterium according to any one of claims 1 to 4, wherein the bacterium has a vector comprising the expression unit. The method according to

6. The method according to any one of claims 1 to 5, wherein the promoter sequence is a promoter according to (a) or (b) below: (a) a promoter comprising the nucleotide sequence shown in SEQ ID NO: 13 or 78; (b) a promoter comprising a base sequence having 90% or more identity to the base sequence shown in SEQ ID NO: 13 or 78.

7. The bacteria according to any one of claims 1 to 6, wherein the bacteria is a bacterium of the genus Corynebacterium.

2. The method according to any one of claims 1 to 11.

8. The method according to any one of claims 1 to 7, wherein the bacterium is Corynebacterium glutamicum.

Images